{"content":"<li class=\"n-box-item date-title\" data-end=\"1490155199\" data-start=\"1490068800\" data-txt=\"Sunday, December 22, 2019\">Tuesday, March 21, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3252631\" data-ts=\"1490151572\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTL\" target=\"_blank\">CTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252631-centurylink-joins-netapp-partner-program-to-re-sell-managed-storage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenturyLink joins NetApp partner program, to re-sell managed storage</a></h4><ul>   <li>CenturyLink (<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a> <font color='red'>-1.2%</font>) has joined the Unified Partner Program at NetApp (<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a> <font color='red'>-2.5%</font>), extending an existing relationship by <a href=\"http://www.lightreading.com/services/managed-services/centurylink-to-resell-netapp-managed-storage-solutions-more/d/d-id/731339?_mc=RSS_LR_EDT\" target=\"_blank\">arranging to re-sell</a> the latter's managed storage solutions.</li>    <li>It's a \"big push in the field,\" CenturyLink's Terence Gleeson tells LightReading. The provider will take six main routes to market, including large enterprise, SMB, government and education, and global teams.</li>    <li>CenturyLink has a number of co-location environments where customers have had NetApp equipment.</li>    <li>It wants to offer customers a complete package, whether they want to manage their own hardware or for CenturyLink to provide a managed service.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252631\" data-linked=\"CenturyLink joins NetApp partner program, to re-sell managed storage\" data-tweet=\"$CTL $CTL $NTAP - CenturyLink joins NetApp partner program, to re-sell managed storage https://seekingalpha.com/news/3252631-centurylink-joins-netapp-partner-program-to-re-sell-managed-storage?source=tweet\" data-url=\"https://seekingalpha.com/news/3252631-centurylink-joins-netapp-partner-program-to-re-sell-managed-storage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252625\" data-ts=\"1490138140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252625-dish-broadcaster-power-driving-hundreds-of-blackouts-skyrocketing-fees\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish: Broadcaster power driving hundreds of blackouts, skyrocketing fees</a></h4><ul>   <li>Dish Network (<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> <font color='red'>-1.9%</font>) -- in the middle of a <a href=\"https://seekingalpha.com/news/3248613\" target=\"_blank\">two-week-old blackout</a> by Hearst Television affiliates -- is calling for \"baseball-style\" arbitration, complaining that the current method of retransmission negotiations is <a href=\"http://www.fiercecable.com/cable/dish-750-blackouts-have-come-as-retrans-fees-have-grown-27-400\" target=\"_blank\">hurting the public</a>.</li>    <li>Laws haven't changed since the current retrans consent regime was set up, but video has, argues Dish's Warren Schlichting in a letter to Silicon Valley Rep. Anna Eshoo.</li>    <li>He says consumers have seen more than 750 blackouts since 2010, and that retransmission consent fees demanded by broadcasters have risen 27,400% between 2005 and 2016.</li>    <li>&ldquo;We agree that it is time for consumers to stop being treated as pawns,&rdquo; Schlichting says in the letter. Hearst, meanwhile, has argued that \"Dish has continued to insist on including material terms that are less favorable than our current agreement.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252625\" data-linked=\"Dish: Broadcaster power driving hundreds of blackouts, skyrocketing fees\" data-tweet=\"$DISH - Dish: Broadcaster power driving hundreds of blackouts, skyrocketing fees https://seekingalpha.com/news/3252625-dish-broadcaster-power-driving-hundreds-of-blackouts-skyrocketing-fees?source=tweet\" data-url=\"https://seekingalpha.com/news/3252625-dish-broadcaster-power-driving-hundreds-of-blackouts-skyrocketing-fees\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252624\" data-ts=\"1490137127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252624-petrobras-reports-q4-profit-20-lower-debt-load\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras reports Q4 profit, 20% lower debt load</a></h4><ul>     <li>Petrobras (NYSE:<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a>) <font color='green'>+2.1%</font> AH after saying it <a href=\"http://www.reuters.com/article/us-petrobras-results-idUSKBN16S2SV\" target=\"_blank\">earned a net profit</a> of 2.51B Brazilian reais ($812M) in Q4, helped by drastic cost cuts and higher well productivity as it reversed a 16.46B real loss in the year-ago quarter caused partly by heavy asset writedowns.</li>     <li>PBR says Q4 revenue came in flat Q/Q at 70.49B reais, lower than expected, but EBITDA rose to 24.79B reais, ahead of expectations.</li>     <li>Net debt fell by a bigger than expected 20% to 314.12B reais (~$118B), helped by a stronger currency and lower borrowing costs, and free cash flow reached 11.95B reais, down 27% Q/Q but in line with most estimates.</li>     <li>Capital spending surprisingly rose 15% in Q4, and the company revises total capex planned for 2017-21 to $74.5B from $74.1B previously.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252624\" data-linked=\"Petrobras reports Q4 profit, 20% lower debt load\" data-tweet=\"$PBR - Petrobras reports Q4 profit, 20% lower debt load https://seekingalpha.com/news/3252624-petrobras-reports-q4-profit-20-lower-debt-load?source=tweet\" data-url=\"https://seekingalpha.com/news/3252624-petrobras-reports-q4-profit-20-lower-debt-load\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252620\" data-ts=\"1490135392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCS\" target=\"_blank\">SCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252620-steelcase-dips-after-posting-mixed-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelcase dips after posting mixed quarter</a></h4><ul>   <li>Steelcase (<a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color='red'>-2.6%</font>) is off another <font color='red'>-0.6%</font> after hours following mixed <a href=\"https://seekingalpha.com/news/3252564-steelcase-misses-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a> where Americas revenue growth powered sales past expectations, but profits narrowly missed.</li>    <li>Revenue by segment: Americas, $563.8M (up 3.4%); EMEA, $130.2M (down 4.5%); other, $75.1M (up 13.4%).</li>    <li>Operating income by segment: Americas, $61M; EMEA, -$6M; other, $4.2M.</li>    <li>The company noted mixed order patterns for Q4 (up 5% in Americas, down 3% in EMEA, up 24% in Other, including record orders in Asia Pacific). It's guiding to Q1 revenue of $725M-$750M (vs. consensus for $745.7M), which would mean organic revenue growth of 2-6%.</li>    <li><a href=\"http://edge.media-server.com/m/p/5dmn4d69\" target=\"_blank\">Conference call</a> to come at 8:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16777518-steelcase-reports-fourth-quarter-fiscal-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252620\" data-linked=\"Steelcase dips after posting mixed quarter\" data-tweet=\"$SCS - Steelcase dips after posting mixed quarter https://seekingalpha.com/news/3252620-steelcase-dips-after-posting-mixed-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3252620-steelcase-dips-after-posting-mixed-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252619\" data-ts=\"1490134730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPM\" target=\"_blank\">WPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252619-silver-wheaton-higher-ah-after-beating-q4-numbers-hiking-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silver Wheaton higher AH after beating Q4 numbers, hiking dividend</a></h4><ul><li>Silver Wheaton (SLW)&nbsp;<font color='green'>+3.4%</font> AH after posting better than expected <a href=\"https://seekingalpha.com/news/3252599-silver-wheaton-beats-0_03-beats-revenue\" target=\"_blank\">Q4 earnings</a> and revenues, plus a <a href=\"https://seekingalpha.com/news/3252600-silver-wheaton-declares-0_07-dividend\" target=\"_blank\">penny increase</a> to its quarterly dividend.</li><li>SLW reports Q4 attributable production of 7.6M oz. of silver, down 26% from 10.3M oz. in the prior-year quarter, and  107.3K oz. of gold, 48% higher than 72.4K&nbsp;oz. in Q4 2015.</li><li>SLW forecasts FY 2017 attributable production of 28M oz. of silver and 340K oz. of gold, assuming the ongoing San Dimas strike will continue for three months and then achieve production  in line with 2016; over the next five years, SLW sees average annual  attributable production in  line with 2017.</li><li>Also, the board recommends changing the  company's name to Wheaton Precious Metals, to better align the corporate identity with a diverse portfolio of both silver and gold assets.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252619\" data-linked=\"Silver Wheaton higher AH after beating Q4 numbers, hiking dividend\" data-tweet=\"$WPM - Silver Wheaton higher AH after beating Q4 numbers, hiking dividend https://seekingalpha.com/news/3252619-silver-wheaton-higher-ah-after-beating-q4-numbers-hiking-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3252619-silver-wheaton-higher-ah-after-beating-q4-numbers-hiking-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252612\" data-ts=\"1490132332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252612-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='green'>+19.6%</font>. <a href='https://seekingalpha.com/symbol/OSIR' title='Osiris Therapeutics, Inc.'>OSIR</a> <font color='green'>+9.6%</font>. <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+3.1%</font>. SLW <font color='green'>+2.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color='red'>-6.1%</font>. <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='red'>-3.0%</font>. <a href='https://seekingalpha.com/symbol/LTXB' title='LegacyTexas Financial Group Inc.'>LTXB</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-2.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252612\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$DLTH $OSIR $ACHN - After Hours Gainers / Losers https://seekingalpha.com/news/3252612-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252612-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252599\" data-ts=\"1490130116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPM\" target=\"_blank\">WPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252599-silver-wheaton-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silver Wheaton beats by $0.03, beats on revenue</a></h4><ul><li>Silver Wheaton (SLW): Q4 EPS of $0.19 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $258M (+28.7% Y/Y) <font color='green'>beats by $13.46M</font>.</li><li>Shares <font color='green'>+1.8%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16777629-silver-wheaton-reports-record-revenue-sales-volumes-2016-announces-proposed-name-change'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252599\" data-linked=\"Silver Wheaton beats by $0.03, beats on revenue\" data-tweet=\"$WPM - Silver Wheaton beats by $0.03, beats on revenue https://seekingalpha.com/news/3252599-silver-wheaton-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3252599-silver-wheaton-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252594\" data-ts=\"1490129248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252594-fedexminus-3_75-after-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx -3.75% after earnings miss</a></h4><ul><li>FQ3 adjusted income of $638M or $2.35 per share vs. $692M and $2.51 one year ago.</li><li>Operating margin of 7.5% down 170 bps Y/Y.</li><li>Company takes note of higher fuel costs and one fewer operating day in this year's quarter.</li><li>Full-year fiscal 2017 earnings are unable to be forecast thanks to year-end MTM pension accounting adjustments. Forgetting those, adjusted EPS is maintained at $11.85-$12.35.</li><li><a href=\"http://investors.fedex.com/news-and-events/upcoming-events/default.aspx\" target=\"_blank\">Earnings call at 5 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3252580-fedex-misses-0_27-revenue-line\" target=\"_blank\">FedEx misses by $0.27,  revenue in-line</a> (March 21)</li><li><a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a><font color='red'> -3.75%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3252594\" data-linked=\"FedEx -3.75% after earnings miss\" data-tweet=\"$FDX - FedEx -3.75% after earnings miss https://seekingalpha.com/news/3252594-fedexminus-3_75-after-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3252594-fedexminus-3_75-after-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252585\" data-ts=\"1490128073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252585-nikeminus-1_6-after-posting-in-line-revenue-growth-for-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike -1.6% after posting in-line revenue growth for its Q3</a></h4><ul>    <li>Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-1.1%</font>) is <font color='red'>off 1.6%</font> in postmarket trade following <a href=\"https://seekingalpha.com/news/3252581-nike-beats-0_15-revenue-line\" target=\"_blank\">fiscal Q3 earnings</a> where revenues were in line after growth across the portfolio, and profits grew even faster.</li><li>The company pushed futures orders discussion to its call, though, and equipment sales dropped (though outpaced by gains in footwear and apparel).</li>    <li>EPS was up 24% vs. revenue's 5% growth, thanks to lower selling/administrative costs, higher other income and a lower tax rate (along with a reduced share count).</li>    <li>Revenues by brand: Nike brand, $7.9B (up 7% ex-currency); Converse, $498M (up 3% ex-currency).</li>    <li>Gross margin fell 140 basis points, to 44.5%, with product costs and forex (among other factors) outstripping higher average selling prices.</li>    <li>Inventories were $4.9B (up 7% Y/Y), though Nike Brand wholesale inventories fell 3%. The company said it would discuss worldwide futures orders (\"as deemed appropriate\") on its earnings call, and post futures charts after the call.</li>    <li><a href=\"http://investors.NIKE.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16777564-nike-inc-reports-fiscal-2017-third-quarter-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252585\" data-linked=\"Nike -1.6% after posting in-line revenue growth for its Q3\" data-tweet=\"$NKE - Nike -1.6% after posting in-line revenue growth for its Q3 https://seekingalpha.com/news/3252585-nikeminus-1_6-after-posting-in-line-revenue-growth-for-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3252585-nikeminus-1_6-after-posting-in-line-revenue-growth-for-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252579\" data-ts=\"1490127286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTL\" target=\"_blank\">VTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252579-vital-therapies-initiates-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vital Therapies initiates equity offering</a></h4><ul><li>Vital Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/VTL' title='Vital Therapies, Inc.'>VTL</a>) <a href=\"https://seekingalpha.com/pr/16777516-vital-therapies-announces-proposed-public-offering-common-stock\" target=\"_blank\">readies </a>a public offering of common stock. Price, volume and terms have yet to be announced. Today's close was $4.30. No after-hours trading has been reported.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252579\" data-linked=\"Vital Therapies initiates equity offering\" data-tweet=\"$VTL $IMUX - Vital Therapies initiates equity offering https://seekingalpha.com/news/3252579-vital-therapies-initiates-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3252579-vital-therapies-initiates-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252575\" data-ts=\"1490127085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGNX\" target=\"_blank\">RGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252575-regenxbio-readies-75m-equity-offering-shares-off-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">REGENXBIO readies $75M equity offering; shares off 8% after hours</a></h4><ul><li>REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>) <a href=\"https://seekingalpha.com/pr/16777519-regenxbio-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a $75M public offering of common stock. Price, volume and terms have yet to be announced. Shares are down 8% after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252575\" data-linked=\"REGENXBIO readies $75M equity offering; shares off 8% after hours\" data-tweet=\"$RGNX - REGENXBIO readies $75M equity offering; shares off 8% after hours https://seekingalpha.com/news/3252575-regenxbio-readies-75m-equity-offering-shares-off-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252575-regenxbio-readies-75m-equity-offering-shares-off-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252570\" data-ts=\"1490126922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTH\" target=\"_blank\">DLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252570-duluth-holdings-beats-0_09-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Duluth Holdings beats by $0.09, beats on revenue</a></h4><ul><li>Duluth Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a>): Q4 EPS of $0.43 <font color='green'>beats by $0.09</font>.</li><li>Revenue of $174.65M (+24.4% Y/Y) <font color='green'>beats by $11.55M</font>.</li><li>Shares <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/pr/16777532-duluth-holdings-inc-announces-fourth-quarter-fiscal-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252570\" data-linked=\"Duluth Holdings beats by $0.09, beats on revenue\" data-tweet=\"$DLTH - Duluth Holdings beats by $0.09, beats on revenue https://seekingalpha.com/news/3252570-duluth-holdings-beats-0_09-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3252570-duluth-holdings-beats-0_09-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252561\" data-ts=\"1490126262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSR\" target=\"_blank\">VSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252561-versarplus-45-on-contract-award-for-johnson-controls-federal-systems-jv\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Versar +45% on contract award for Johnson Controls Federal Systems JV</a></h4><ul><li>Versar (<a href='https://seekingalpha.com/symbol/VSR' title='Versar, Inc'>VSR</a> <font color='green'>+45.1%</font>) is soaring nearly 50% today following news that its long-term joint venture with Johnson Controls (<a href='https://seekingalpha.com/symbol/JCI' title='Johnson Controls International plc'>JCI</a> <font color='red'>-2.1%</font>) Federal Systems joint venture  was <a href=\"http://www.versar.com/news/WEC-IDIQ.pdf\" target=\"_blank\">awarded</a> the Worldwide Engineering &amp; Construction Indefinite Delivery Indefinite Quantity contract by the U.S. Air Force.</li><li>The WE&amp;C contract ceiling is $950M over a five-year base period and three additional one-year option periods; individual task orders will be competed among the 11 selected firms.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252561\" data-linked=\"Versar +45% on contract award for Johnson Controls Federal Systems JV\" data-tweet=\"$VSR $VSR $JCI - Versar +45% on contract award for Johnson Controls Federal Systems JV https://seekingalpha.com/news/3252561-versarplus-45-on-contract-award-for-johnson-controls-federal-systems-jv?source=tweet\" data-url=\"https://seekingalpha.com/news/3252561-versarplus-45-on-contract-award-for-johnson-controls-federal-systems-jv\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252560\" data-ts=\"1490125500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBRL\" target=\"_blank\">CBRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252560-cracks-appear-in-cracker-barrels-bull-thesis-argus-says-in-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cracks appear in Cracker Barrel&#39;s bull thesis, Argus says in downgrade</a></h4><ul>     <li>Cracker Barrel (<a href='https://seekingalpha.com/symbol/CBRL' title='Cracker Barrel Old Country Store, Inc.'>CBRL</a> <font color='red'>-1.7%</font>) is <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9196768/cracks-appear-in-cracker-barrels-bull-thesis\" target=\"_blank\">downgraded</a> to Hold from Buy at Argus, which expects customer traffic to remain weak and same-store sales growth to  decelerate over the next several quarters.</li>     <li>Although CBRL reported better than expected <a href=\"https://seekingalpha.com/news/3244743-cracker-barrel-beats-0_05-misses-revenue\" target=\"_blank\">Q2 earnings</a>, it maintained its full-year EPS estimate, &ldquo;implying slower growth in the second half of the year,&rdquo; Argus says in reducing its EPS estimates for FY 2017 and 2018 to $8.20 from $8.30 and to $8.84 from $8.88, respectively.</li>     <li>Cracker Barrel&rsquo;s stock is trading slightly above the multiples of Darden Restaurants (<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a> <font color='red'>-0.3%</font>), which Argus believes has stronger near-term growth prospects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252560\" data-linked=\"Cracks appear in Cracker Barrel&#39;s bull thesis, Argus says in downgrade\" data-tweet=\"$CBRL $CBRL $DRI - Cracks appear in Cracker Barrel&#39;s bull thesis, Argus says in downgrade https://seekingalpha.com/news/3252560-cracks-appear-in-cracker-barrels-bull-thesis-argus-says-in-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3252560-cracks-appear-in-cracker-barrels-bull-thesis-argus-says-in-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252559\" data-ts=\"1490125443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDRX\" target=\"_blank\">MDRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252559-allscripts-hosts-investor-day-sees-three-year-eps-growth-high-15-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allscripts hosts investor day, sees three-year EPS growth as high as 15%; shares ahead 2%</a></h4><ul><li>Allscripts (<a href='https://seekingalpha.com/symbol/MDRX' title='Allscripts Healthcare Solutions, Inc.'>MDRX</a> <font color='green'>+2.2%</font>) bucks the market's sour mood. Shares are up on almost double normal volume. Investors are in a buying mood after the company's presentation at its Investor Day.</li><li>Management reiterated the guidance it released a month ago and added three-year CAGR targets of 6 - 8% for non-GAAP revenues and 12 - 15% for non-GAAP EPS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252559\" data-linked=\"Allscripts hosts investor day, sees three-year EPS growth as high as 15%; shares ahead 2%\" data-tweet=\"$MDRX - Allscripts hosts investor day, sees three-year EPS growth as high as 15%; shares ahead 2% https://seekingalpha.com/news/3252559-allscripts-hosts-investor-day-sees-three-year-eps-growth-high-15-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3252559-allscripts-hosts-investor-day-sees-three-year-eps-growth-high-15-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252557\" data-ts=\"1490124951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252557-canadian-solar-not-seeing-major-trump-impact-on-u-s-solar-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar not seeing major Trump impact on U.S. solar sales</a></h4><ul><li>Canadian Solar (<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-9.1%</font>) CEO and President Shawn Qu says Pres. Trump&rsquo;s pro-coal and pro-fossil fuel policies <a href=\"http://business.financialpost.com/news/energy/donald-trumps-shadow-looms-large-over-canadian-solars-prospects\" target=\"_blank\">have not hurt sales</a> of the company's solar cells in the U.S., but the U.S. Department of Commerce dealt a significant setback with the preliminary release of revised anti-dumping tariffs.</li><li>CSIQ says it is strongly contesting the early results of the DoC's revised anti-dumping and other tariffs on Chinese-manufactured solar panels, which Qu says are &ldquo;hugely different from the past rates imposed on the company.&rdquo;</li><li>&ldquo;We believe that technology is what set the winners apart from the losses in this run of the industry cycle,&rdquo; Qu said in today's earnings conference call, adding that CSIQ plans to raise its solar cell manufacturing capacity even as competitors cut back.</li><li>CSIQ's revenues, profits and margins all have <a href=\"https://seekingalpha.com/news/3252484-canadian-solar-minus-9-percent-q4-miss-guides-q1-revenue-consensus\" target=\"_blank\">declined over the past year</a> due to &ldquo;the industry-wide declines in average selling price that have been persistent all year,\" although the company set records for solar module shipments in Q4 and FY 2016, and Qu says demand for its products remains firm.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252557\" data-linked=\"Canadian Solar not seeing major Trump impact on U.S. solar sales\" data-tweet=\"$CSIQ - Canadian Solar not seeing major Trump impact on U.S. solar sales https://seekingalpha.com/news/3252557-canadian-solar-not-seeing-major-trump-impact-on-u-s-solar-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3252557-canadian-solar-not-seeing-major-trump-impact-on-u-s-solar-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252555\" data-ts=\"1490124753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252555-twitter-suspended-636000-accounts-in-fighting-extremism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter: We&#39;ve suspended 636,000 accounts in fighting extremism</a></h4><ul>   <li>In a move to counter \"violent extremism\" in its user ranks, Twitter (<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='red'>-3.5%</font>) says it's <a href=\"http://www.reuters.com/article/us-twitter-extremism-idUSKBN16S1Z4\" target=\"_blank\">suspended more than 636,000 user accounts</a> since 2015.</li>    <li>That includes 376,890 shut down in the last six months of last year.</li>    <li>The company's under pressure from rivals competing to draw advertisers to their platforms, in a general environment where social media companies are increasingly policing their ranks to weed out lawbreakers.</li>    <li>The news comes in the wake of reports that as much as <a href=\"https://seekingalpha.com/news/3252119-twitter-bot-accounts-weigh-dorsey\" target=\"_blank\">15% of the account base isn't human</a> (up to 48M accounts, more than twice the company's estimate).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252555\" data-linked=\"Twitter: We&#39;ve suspended 636,000 accounts in fighting extremism\" data-tweet=\"$TWTR - Twitter: We&#39;ve suspended 636,000 accounts in fighting extremism https://seekingalpha.com/news/3252555-twitter-suspended-636000-accounts-in-fighting-extremism?source=tweet\" data-url=\"https://seekingalpha.com/news/3252555-twitter-suspended-636000-accounts-in-fighting-extremism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252551\" data-ts=\"1490124500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252551-synapticsminus-7_4-cowen-and-company-reiterates-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics -7.4%; Cowen and Company reiterates Outperform</a></h4><ul><li>Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>), trading at a pronounced reduction even amid a broader market sell-off, is defended following reaction attributed to current (demand from OEM customers, channel inventory backlog) and expected near-term weakness realized at Swedish biometric firm Fingerprint Cards, leading that company to <a href=\"https://corporate.fingerprints.com/en/2017/03/21/fingerprint-cards-ab-expects-an-even-weaker-q1-and-the-short-term-challenges-to-prevail-in-q2/\" target=\"_blank\">withdraw</a>&nbsp;its 2017 revenue guidance.&nbsp;<a href=\"http://blogs.barrons.com/techtraderdaily/2017/03/21/synaptics-dont-panic-on-fingerprint-news-says-cowen/\" target=\"_blank\">Analyst Robert Stone</a>: \"We believe SYNA sells directly to OEMs.&nbsp;We estimate SYNA derives less than 25% of sales from fingerprint sensors and less than 35% from customers in greater China. Samsung accounts for the vast majority of SYNA fingerprint sensor revenue and is about to launch the Galaxy S8 in two sizes. SYNA has an optical, under the bezel-glass solution expected to be ready for mass production in Q2, and a display-integrated fingerprint sensor, which should ship in H2:CY17. We believe these are ahead of similar offerings from competitors.\" Further considers positioned for market share gains, price target $75 (current $47.72).</li><li>Earlier (March 21, 2017): <a href=\"https://seekingalpha.com/news/3252480-synaptics-minus-5_6-percent-following-guidance-withdrawal-fingerprint-cards\" target=\"_blank\">Synaptics -5.6% following guidance withdrawal at Fingerprint Cards</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252551\" data-linked=\"Synaptics -7.4%; Cowen and Company reiterates Outperform\" data-tweet=\"$SYNA - Synaptics -7.4%; Cowen and Company reiterates Outperform https://seekingalpha.com/news/3252551-synapticsminus-7_4-cowen-and-company-reiterates-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3252551-synapticsminus-7_4-cowen-and-company-reiterates-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252548\" data-ts=\"1490122961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252548-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SILC' title='Silicom Ltd'>SILC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QTNA' title='Quantenna Communications'>QTNA</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VLTC' title='Voltari Corporation'>OTC:VLTC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252548\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$SILC $XGTI-OLD $SCON - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3252548-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252548-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252549\" data-ts=\"1490122764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252549-rite-aid-shares-be-cut-in-half-walgreens-deal-fails-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid shares could be cut in half if Walgreens deal fails, analyst says</a></h4><ul>     <li>Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-4.4%</font>) <a href=\"http://thefly.com/landingPageNews.php?id=2522750&amp;headline=RAD;WBA;FRED-Deutsche-says-Rite-Aid-could-fall--if-Walgreens-deal-fails\" target=\"_blank\">could tumble to as low as $2.25</a> in a worst case scenario - more than 50% from current levels - if its merger with&nbsp;Walgreens Boots Alliance (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='red'>-1.3%</font>) fails to go through, Deutsche Bank analyst George Hill warns, adding that WBA shares have downside to the $73-$79 range, or as much as 14%.</li>     <li>According to TheFly.com, Hill believes a key to WBA's decision to certify compliance with the FTC's second request to address concerns about the proposed merger could involve the agency's current makeup, which has three vacant seats along with the Republican chair and a Democrat member.</li><li>Hill has a Buy rating on WBA with a $92 price target, which excludes RAD.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3252549\" data-linked=\"Rite Aid shares could be cut in half if Walgreens deal fails, analyst says\" data-tweet=\"$RAD $RAD $WBA - Rite Aid shares could be cut in half if Walgreens deal fails, analyst says https://seekingalpha.com/news/3252549-rite-aid-shares-be-cut-in-half-walgreens-deal-fails-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3252549-rite-aid-shares-be-cut-in-half-walgreens-deal-fails-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>168&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252545\" data-ts=\"1490122630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QHC\" target=\"_blank\">QHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252545-hospital-names-hit-hardest-trumpcare-makes-progress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospital names hit hardest as Trumpcare makes progress</a></h4><ul><li>According to House Speaker Paul Ryan, the president today \"hit it out of the park,\" in his trip to Capital Hill to convince GOP members to vote for the Obamacare repeal.</li><li>The quick take is that the proposed replacement would cover fewer people, meaning less money/more unpaid bills for hospitals.</li><li>The Bloomberg Intelligence North America Hospitals Index today&nbsp;<font color='red'>fell as much as 5.5%</font>, led by by Quorum Health (<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-9.8%</font>), Community Health (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='red'>-7.2%</font>), Tenet Health (<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='red'>-5.5%</font>), HCA Holdings (<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='red'>-1.3%</font>), and LifePoint Health (<a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a> <font color='red'>-1.2%</font>).</li><li>Mizuho says Quorum has \"material\" Medicaid expansion exposure with limited operation scale, and thus fewer ways to offset any rollback. LifePoint and Tenet also have Medicare exposure.</li><li>HCA remains best-positioned to weather the challenges.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252545\" data-linked=\"Hospital names hit hardest as Trumpcare makes progress\" data-tweet=\"$QHC $QHC $CYH - Hospital names hit hardest as Trumpcare makes progress https://seekingalpha.com/news/3252545-hospital-names-hit-hardest-trumpcare-makes-progress?source=tweet\" data-url=\"https://seekingalpha.com/news/3252545-hospital-names-hit-hardest-trumpcare-makes-progress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252544\" data-ts=\"1490121870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BEBE\" target=\"_blank\">BEBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252544-bebe-storesminus-25-said-to-close-stores-in-bid-to-stave-off-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bebe Stores -25%, said to close stores in bid to stave off bankruptcy</a></h4><ul>     <li>Bebe Stores (<a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a> <font color='red'>-25.3%</font>) sinks in reaction to a Bloomberg report that the company is <a href=\"https://www.bloomberg.com/news/articles/2017-03-21/bebe-said-to-plan-to-shut-its-stores-in-brick-and-mortar-retreat\" target=\"_blank\">planning to shut its brick and mortar stores</a> and seek a turnaround as&nbsp;an online brand.</li>     <li>Bebe is trying to close the locations without filing for bankruptcy, but Chapter 11 may be required if enough landlords are not willing to negotiate, according to the report.</li>     <li>Bebe has no significant debt, unlike many retailers, but the company has lost ~$200M over the past four years, and negotiating with landlords to get out of leases may prove difficult.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252544\" data-linked=\"Bebe Stores -25%, said to close stores in bid to stave off bankruptcy\" data-tweet=\"$BEBE - Bebe Stores -25%, said to close stores in bid to stave off bankruptcy https://seekingalpha.com/news/3252544-bebe-storesminus-25-said-to-close-stores-in-bid-to-stave-off-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3252544-bebe-storesminus-25-said-to-close-stores-in-bid-to-stave-off-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252540\" data-ts=\"1490121079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDG\" target=\"_blank\">TDG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252540-transdigm-down-nearly-another-10-on-call-for-government-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransDigm down nearly another 10% on call for government probe</a></h4><ul><li>California Representative Ro Khanna<a href=\"https://khanna.house.gov/media/press-releases/release-rep-khanna-calls-investigation-aerospace-defense-contractor-business\" target=\"_blank\"> today sent a letter </a>to the Pentagon calling for an investigation into business practices at TransDigm (<a href='https://seekingalpha.com/symbol/TDG' title='TransDigm Group Incorporated'>TDG</a> <font color='red'>-9.6%</font>).</li><li>From his PR: \"Recent news reports indicate that TransDigm may be operating as a 'hidden monopolist' and more information must be made available to the public on the company&rsquo;s business practices.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3250442-transdigm-minus-4-percent-left-talks-bloomberg\" target=\"_blank\">TransDigm -4% as Left talks to Bloomberg</a> (March 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252540\" data-linked=\"TransDigm down nearly another 10% on call for government probe\" data-tweet=\"$TDG - TransDigm down nearly another 10% on call for government probe https://seekingalpha.com/news/3252540-transdigm-down-nearly-another-10-on-call-for-government-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3252540-transdigm-down-nearly-another-10-on-call-for-government-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252538\" data-ts=\"1490119921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252538-gold-gains-again-stocks-sell-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold gains again as stocks sell off</a></h4><ul><li>With the major averages&nbsp;<font color='red'>down 1% or more</font>, the bid stays strong for gold, up&nbsp;<font color='green'>another 1.1%</font>&nbsp;today to $1,247 per ounce - now<font color='green'> up by about $50&nbsp;</font>since the Fed hiked rates last Wednesday. Silver is&nbsp;<font color='green'>ahead 0.9%</font>&nbsp;to $17.59 per ounce.</li><li>The gold and silver miners, in turn, are about the only sectors in the green this session, with the <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>&nbsp;<font color='green'>higher by 2.1%</font>, and <a href='https://seekingalpha.com/symbol/SIL' title='Global X Silver Miners ETF'>SIL</a>&nbsp;<font color='green'>by 1.8%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='ETFS Physical Swiss Gold Trust ETF'>SGOL</a>, <a href='https://seekingalpha.com/symbol/ZSL' title='ProShares UltraShort Silver ETF'>ZSL</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='PowerShares DB Gold ETF'>DGL</a>, <a href='https://seekingalpha.com/symbol/DBS' title='PowerShares DB Silver ETF'>DBS</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/USV' title='UBS ETRACS CMCI Silver Total Return ETN'>USV</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a>, <a href='https://seekingalpha.com/symbol/DULL' title='Direxion Daily Silver Miners Index Bear 2x Shares ETF'>DULL</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a>, <a href='https://seekingalpha.com/symbol/SHNY' title='Direxion Daily Silver Miners Index Bull 2x Shares ETF'>SHNY</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252538\" data-linked=\"Gold gains again as stocks sell off\" data-tweet=\"$GDX $SIL $GLD - Gold gains again as stocks sell off https://seekingalpha.com/news/3252538-gold-gains-again-stocks-sell-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3252538-gold-gains-again-stocks-sell-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252536\" data-ts=\"1490119259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252536-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HGT-OLD' title='Hugoton Royalty Trust'>HGT-OLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ECT' title='ECA Marcellus Trust I'>ECT</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252536\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$HGT-OLD $HOS $WLB - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3252536-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252536-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252533\" data-ts=\"1490119026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252533-retailersminus-2-brady-promises-border-tax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retailers -2% as Brady promises border tax</a></h4><ul><li>\"My sense is that border adjustability has become a given,\" <a href=\"http://blogs.barrons.com/focusonfunds/2017/03/21/why-retailers-are-getting-wrecked/?mod=BOL_hp_blog_fof\" target=\"_blank\">says Kevin Brady</a>, head of the House's Ways &amp; Means Committee, and thus kind of powerful when it comes to writing tax laws.</li><li>That doesn't sound good for retailers, says Peter Boockvar. The good news, though, is a Senate that appears to be standing in the way of the border tax plans of the president and the House.</li><li>Retailers (<a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a> <font color='red'>-2%</font>) are nevertheless about doubling the S&amp;P 500's decline today, with Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='red'>-4.3%</font>) joining <a href=\"https://seekingalpha.com/news/3252473-losses-kohls-macys-q1-caution\" target=\"_blank\">Macy's and Kohl's </a>in being particularly hard hit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252533\" data-linked=\"Retailers -2% as Brady promises border tax\" data-tweet=\"$GPS $XRT $GPS - Retailers -2% as Brady promises border tax https://seekingalpha.com/news/3252533-retailersminus-2-brady-promises-border-tax?source=tweet\" data-url=\"https://seekingalpha.com/news/3252533-retailersminus-2-brady-promises-border-tax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252529\" data-ts=\"1490116743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252529-mallinckrodtminus-3_6-bi-story-questions-achtar-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt -3.6%: BI story questions Achtar spending</a></h4><ul><li>\"Tell me if this makes sense to you,\" <a href=\"http://www.businessinsider.com/acthar-risks-including-doctors-prescribing-and-efficacy-questions-2017-3\" target=\"_blank\">writes Linette Lopez</a>. In 2015, the U.S. government spent more than $500M on a $38K non-lifesaving drug with a wide range of cheaper alternatives, making that drug one of the top 20 expenses for Medicare Part D.</li><li>Further, that drug (Achtar) is prescribed by less than 1% of U.S. doctors, according to an Oregon State study being cited by critics and short-sellers of&nbsp;Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='red'>-3.6%</font>).</li><li>Oregon State's&nbsp;Dennis Bourdette: \"The list of indications from the FDA are infantile spasms, multiple sclerosis, and then all these other indications that the neurologist and rheumatologist prescribe it for ...&nbsp;There have never been any designed controlled trials or any basis that show that it's superior to synthetic steroids, which brings up the question &mdash; who are these people and why are they prescribing this when we have synthetic steroids that work?\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3252529\" data-linked=\"Mallinckrodt -3.6%: BI story questions Achtar spending\" data-tweet=\"$MNK - Mallinckrodt -3.6%: BI story questions Achtar spending https://seekingalpha.com/news/3252529-mallinckrodtminus-3_6-bi-story-questions-achtar-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/3252529-mallinckrodtminus-3_6-bi-story-questions-achtar-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252528\" data-ts=\"1490116551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAAS\" target=\"_blank\">PAAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252528-pan-american-silver-upgraded-to-outperform-rbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pan American Silver upgraded to Outperform at RBC</a></h4><ul><li>Pan American Silver (<a href='https://seekingalpha.com/symbol/PAAS' title='Pan American Silver Corp.'>PAAS</a> <font color='green'>+3.6%</font>) surges as RBC&nbsp;Capital <a href=\"https://www.streetinsider.com/Upgrades/RBC+Capital+Upgrades+Pan+Am+Silver+%28PAAS%29+to+Outperform/12689433.html\" target=\"_blank\">upgrades</a> shares to Outperform from Sector Perform and sets a $22 stock price target, supported by the company's attractive valuation relative to peers.</li><li>RBC expects PAAS to outpace peers as it brings two significant brownfield expansion  projects on-line, advances Joaquin and La Negra, and continues to  deliver steady operating results with potential upside to current  guidance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252528\" data-linked=\"Pan American Silver upgraded to Outperform at RBC\" data-tweet=\"$PAAS - Pan American Silver upgraded to Outperform at RBC https://seekingalpha.com/news/3252528-pan-american-silver-upgraded-to-outperform-rbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3252528-pan-american-silver-upgraded-to-outperform-rbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252626\" data-ts=\"1490115854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCEL\" target=\"_blank\">FCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252626-fuelcell-energy-koreas-posco-reach-asian-fuel-cell-development-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FuelCell Energy, Korea&#39;s Posco reach Asian fuel cell development deal</a></h4><ul>     <li>FuelCell Energy (<a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='green'>+7.4%</font>) announces an MoU with South Korea's Posco (<a href='https://seekingalpha.com/symbol/PKX' title='POSCO'>PKX</a> <font color='red'>-4.6%</font>) to use an existing FCEL subsidiary to directly develop the Asian fuel cell business to expand Asian market opportunities.</li>     <li>Under the agreement, FCEL will market the entire suite of  SureSource solutions in South Korea as well as the broader Asian markets for the  supply, recovery and storage of energy.</li>     <li>PKX will continue to support existing South Korean fuel cell installations and commit to a specified level of module purchases from FCEL to supplement its own local manufacturing for servicing its  existing fleet.</li>     <li>FCEL says the companies expect to finalize a detailed definitive agreement by fall 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252626\" data-linked=\"FuelCell Energy, Korea&#39;s Posco reach Asian fuel cell development deal\" data-tweet=\"$FCEL $FCEL $PKX - FuelCell Energy, Korea&#39;s Posco reach Asian fuel cell development deal https://seekingalpha.com/news/3252626-fuelcell-energy-koreas-posco-reach-asian-fuel-cell-development-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3252626-fuelcell-energy-koreas-posco-reach-asian-fuel-cell-development-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252524\" data-ts=\"1490115036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252524-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VSR' title='Versar, Inc'>VSR</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/SILC' title='Silicom Ltd'>SILC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/HGT-OLD' title='Hugoton Royalty Trust'>HGT-OLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/AST' title='Asterias Biotherapeutics, Inc.'>AST</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BBGI' title='Beasley Broadcast Group, Inc.'>BBGI</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a> <font color='red'>-19%</font>. SSH <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/LAYN' title='Layne Christensen Company'>LAYN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SBLK' title='Star Bulk Carriers Corp.'>SBLK</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252524\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$VSR $PULM $SILC - Midday Gainers / Losers https://seekingalpha.com/news/3252524-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252524-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252522\" data-ts=\"1490113987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAK\" target=\"_blank\">NAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252522-northern-dynasty-says-filed-joint-motion-epa-to-extend-pebble-stay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northern Dynasty says filed joint motion with EPA to extend Pebble stay</a></h4><ul><li>Northern Dynasty Minerals (<a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='red'>-7.1%</font>) is sharply lower today but still nearly 20% higher since Friday after announcing that its  Pebble partnership  and the EPA <a href=\"http://www.northerndynastyminerals.com/ndm/NewsReleases.asp?ReportID=783298\" target=\"_blank\">filed a joint motion</a> in federal court to extend a stay of proceedings in ongoing  litigation.</li><li>NAK says it has made substantial progress in recent discussions with  the EPA and will continue to negotiate the matter directly rather than  through mediation.</li><li>Also, Alaska's two U.S. senators and sole U.S. House member reportedly sent a letter to EPA chief Scott Pruitt asking to reverse the agency's \"recent pattern of preemptive  and retroactive vetoes\" related to the Pebble project.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252522\" data-linked=\"Northern Dynasty says filed joint motion with EPA to extend Pebble stay\" data-tweet=\"$NAK - Northern Dynasty says filed joint motion with EPA to extend Pebble stay https://seekingalpha.com/news/3252522-northern-dynasty-says-filed-joint-motion-epa-to-extend-pebble-stay?source=tweet\" data-url=\"https://seekingalpha.com/news/3252522-northern-dynasty-says-filed-joint-motion-epa-to-extend-pebble-stay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252518\" data-ts=\"1490113872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXAS\" target=\"_blank\">EXAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252518-exact-sciences-says-investor-conference-cancellation-due-to-scheduling-conflict\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exact Sciences says investor conference cancellation due to scheduling conflict</a></h4><ul><li>Quick-trigger traders who rushed into Exact Sciences (<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='red'>-2.7%</font>) earlier in the session on the news that it canceled its presentation at Deutsche Bank's Health Care conference in early May are feeling a bit disheartened after a company representative stated that the cancellation was merely due to a scheduling conflict. There have been instances in the past where such a cancellation preceded an announcement of a merger or acquisition.</li><li>Exact is still on the agenda to deliver a corporate presentation at Bank of America Merrill Lynch's Health Care Conference several weeks later.</li><li>Shares were briefly in the green about an hour after the open but could not hold on to the gain.</li><li>Source: The Fly</li></ul><div class=\"tiny-share-widget\" data-id=\"3252518\" data-linked=\"Exact Sciences says investor conference cancellation due to scheduling conflict\" data-tweet=\"$EXAS - Exact Sciences says investor conference cancellation due to scheduling conflict https://seekingalpha.com/news/3252518-exact-sciences-says-investor-conference-cancellation-due-to-scheduling-conflict?source=tweet\" data-url=\"https://seekingalpha.com/news/3252518-exact-sciences-says-investor-conference-cancellation-due-to-scheduling-conflict\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252520\" data-ts=\"1490113727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252520-nike-slips-nearly-1-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike slips nearly 1% ahead of earnings</a></h4><ul><li>The company is set to report after the close today, and&nbsp;Canaccord Genuity&rsquo;s Camilo Lyon <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/21/nike-4-reasons-to-fear-earnings/?mod=BOL_hp_blog_stw\" target=\"_blank\">says he's yet to see</a> evidence Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-1.1%</font>) is regaining market share even as the stock has advanced 13% this year.</li><li>He thinks it will be spring 2018 at the earlier until material improvement in Nike's offerings can compete with Adidas. Four reasons: 1) Share gains by Adidas and Puma have not slowed 2) Industry contacts indicate Nike's product pipeline remains devoid of signifiant innovation 3) Jordan product is readily available, meaning Nike is trying to stem share losses 4) Supplier signals have not improved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252520\" data-linked=\"Nike slips nearly 1% ahead of earnings\" data-tweet=\"$NKE - Nike slips nearly 1% ahead of earnings https://seekingalpha.com/news/3252520-nike-slips-nearly-1-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3252520-nike-slips-nearly-1-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252513\" data-ts=\"1490112569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252513-biotechs-under-pressure-after-trump-again-decries-high-drug-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs under pressure after Trump (again) decries high drug prices</a></h4><ul><li>The general market's down day notwithstanding, investors appear to be saying one thing and doing another. Supposedly, the market has become less sensitized to President Trump's populist rhetoric about high drug prices and how his administration intends to attack the \"problem.\" Today's sell-off indicates that quite a bit of sensitivity remains.</li><li>Representative tickers: (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='red'>-1.4%</font>)(<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='red'>-2.7%</font>)(<a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a> <font color='red'>-4.4%</font>)(<a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a> <font color='red'>-3.7%</font>)(<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color='red'>-0.9%</font>)(<a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/IHI' title='iShares U.S. Medical Devices ETF'>IHI</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/XHE' title='SPDR S&P Health Care Equipment ETF'>XHE</a> <font color='red'>-0.6%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+1.7%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-1%</font>)(<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+0.5%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+0.4%</font>)(VRX <font color='red'>-0.8%</font>)(<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='red'>-0.1%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-1.7%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+0.1%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252402-president-trump-forgotten-issue-high-drug-prices\" target=\"_blank\">President Trump has not forgotten issue of high drug prices</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252513\" data-linked=\"Biotechs under pressure after Trump (again) decries high drug prices\" data-tweet=\"$BIIB $IBB $BIB - Biotechs under pressure after Trump (again) decries high drug prices https://seekingalpha.com/news/3252513-biotechs-under-pressure-after-trump-again-decries-high-drug-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3252513-biotechs-under-pressure-after-trump-again-decries-high-drug-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252514\" data-ts=\"1490112553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MET\" target=\"_blank\">MET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252514-bank-bulls-bail-bofaminus-4_5-leads-decline-kass-says-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank bulls bail; BofA -4.5% leads decline: Kass says &quot;short&quot;</a></h4><ul><li>\"Group stink has never been more conspicuous than in financial sector stocks,\" <a href=\"http://www.realclearmarkets.com/articles/2017/03/21/a_long_course_on_why_you_should_be_short_financials_102599.html\" target=\"_blank\">says Doug Kass</a>, calling the top in the piping hot names.</li><li>A strong economy, eased regulation, and higher interest rates have all been fully baked into valuations, says Kass, but being ignored: signs of a slowing economy, peaking auto sales, growing protectionism, and valuations at pre-crisis levels.</li><li>Then there's the housing market, and it's \"reached an inflection point in price and activity,\" says Kass. He notes prices of higher-end West and East coast homes have turned lower - usually a bell-ringer for the residential housing cycle.</li><li>Favored shorts: MetLife (<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='red'>-1.1%</font>), Lincoln Financial (<a href='https://seekingalpha.com/symbol/LNC' title='Lincoln National Corporation'>LNC</a> <font color='red'>-2.9%</font>), Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-2%</font>), Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-2.7%</font>). Others he's eyeing: Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-4.4%</font>), Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-0.8%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='red'>-1.3%</font>).</li><li>One name he's a fan of is Hartford Financial (<a href='https://seekingalpha.com/symbol/HIG' title='Hartford Financial Services Group Inc.'>HIG</a> <font color='red'>-0.5%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3252514\" data-linked=\"Bank bulls bail; BofA -4.5% leads decline: Kass says &quot;short&quot;\" data-tweet=\"$MET $MET $LNC - Bank bulls bail; BofA -4.5% leads decline: Kass says &quot;short&quot; https://seekingalpha.com/news/3252514-bank-bulls-bail-bofaminus-4_5-leads-decline-kass-says-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3252514-bank-bulls-bail-bofaminus-4_5-leads-decline-kass-says-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252509\" data-ts=\"1490112059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252509-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/MSN' title='Emerson Radio Corp'>MSN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/JBSS' title='John B. Sanfilippo & Son, Inc.'>JBSS</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252509\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$VNCE $LBIX-OLD $MSN - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3252509-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252509-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252506\" data-ts=\"1490111944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252506-susquehanna-reiterates-micron-technology-positive-elevates-target-to-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna reiterates Micron Technology at Positive, elevates target to $31</a></h4><ul><li>From $29, <a href=\"http://www.streetinsider.com/Analyst+Comments/Micron+Technology+%28MU%29+PT+Raised+to+%2431+at+Susquehanna+Ahead+of+323+Report%3B+All+About+Cost+Execution/12689393.html\" target=\"_blank\">analyst Mehdi Hosseini</a> recalculates factoring Micron Technology's <a href=\"https://seekingalpha.com/news/3248248-micron-technology-plus-1_85-percent-q2-2017-expected-high-end-guidance\" target=\"_blank\">Q2 pre-announcement</a>&nbsp;(reporting <a href=\"http://investors.micron.com/disclaimer.cfm?eventid=180250\" target=\"_blank\">scheduled for Thursday</a>)&nbsp;as well as combined DRAM and NAND ASP reductions firm projects to commence in H2 2017. Model implies EPS peak of $0.90-$0.95 and quarterly gross margin peak of roughly 37% (similar to 2014 top) in the H2 2017 period.</li><li>Micron Technology (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='red'>-1.6%</font>) $25.80.</li><li>Yesterday (March 20, 2017): <a href=\"https://seekingalpha.com/news/3252281-instinet-reiterates-micron-technology-buy\" target=\"_blank\">Instinet reiterates Micron Technology at Buy</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252506\" data-linked=\"Susquehanna reiterates Micron Technology at Positive, elevates target to $31\" data-tweet=\"$MU - Susquehanna reiterates Micron Technology at Positive, elevates target to $31 https://seekingalpha.com/news/3252506-susquehanna-reiterates-micron-technology-positive-elevates-target-to-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3252506-susquehanna-reiterates-micron-technology-positive-elevates-target-to-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252505\" data-ts=\"1490111896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252505-tumble-in-banks-leads-selloff-interest-rates-and-oil-prices-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tumble in banks leads selloff as interest rates and oil prices fall</a></h4><ul><li>The 10-year yield is down another three basis to 2.42% amid a renewed selloff in energy, with oil (NYSEARCA:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>)&nbsp;<font color='red'>down 1.5%</font>&nbsp;to $47.50 per barrel.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.75</font>%, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.5%</font></li><li>The Financial Sector SPDR (<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='red'>-2%</font>), the KBW Regional Banking ETF (<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> <font color='red'>-4.1%</font>), the KBW Bank SPDR (<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> <font color='red'>-4.1%</font>)</li><li>The Nasdaq 100 (<a href='https://seekingalpha.com/symbol/QQQ' title='PowerShares QQQ Trust ETF'>QQQ</a> <font color='red'>-0.8%</font>), S&amp;P 500 (<a href='https://seekingalpha.com/symbol/SPY' title='SPDR S&P 500 Trust ETF'>SPY</a> <font color='red'>-0.8%</font>), DJIA (<a href='https://seekingalpha.com/symbol/DIA' title='SPDR Dow Jones Industrial Average ETF'>DIA</a> <font color='red'>-0.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252505\" data-linked=\"Tumble in banks leads selloff as interest rates and oil prices fall\" data-tweet=\"$USO $TLT $TBT - Tumble in banks leads selloff as interest rates and oil prices fall https://seekingalpha.com/news/3252505-tumble-in-banks-leads-selloff-interest-rates-and-oil-prices-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/3252505-tumble-in-banks-leads-selloff-interest-rates-and-oil-prices-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252496\" data-ts=\"1490108945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMS\" target=\"_blank\">FMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252496-fresenius-down-3-on-sell-rating-ubs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fresenius down 3% on Sell rating by UBS</a></h4><ul><li>Fresenius Medical Care (<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGAA'>FMS</a> <font color='red'>-3.1%</font>) slumps on light volume in apparent response to a <a href=\"http://www.cerclefinance.com/default.asp?pub=valactu&amp;isin=DE0005785802&amp;art=478503\" target=\"_blank\">downgrade</a> to Sell by UBS in addition to trimming the price target to 68 euros from 100 euros.</li><li>In a note to investors, the brokerage firm cited margins \"close to peak\" and catalysts for their fall \"beginning to crystallize.\" It also mentioned comments by the Trump administration that could \"delay or even cancel\" its previous thesis on value-based dialysis care.</li><li>Two shops that updated coverage on FMS this month, Sanford Bernstein and DZ Bank AG, both rate the stock a Buy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252496\" data-linked=\"Fresenius down 3% on Sell rating by UBS\" data-tweet=\"$FMS - Fresenius down 3% on Sell rating by UBS https://seekingalpha.com/news/3252496-fresenius-down-3-on-sell-rating-ubs?source=tweet\" data-url=\"https://seekingalpha.com/news/3252496-fresenius-down-3-on-sell-rating-ubs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252493\" data-ts=\"1490108466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252493-healthcare-top-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/AST' title='Asterias Biotherapeutics, Inc.'>AST</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/OSUR' title='OraSure Technologies, Inc.'>OSUR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast'>MESO</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> SSH <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252493\" data-linked=\"Healthcare - Top Gainers / Losers as of 11:00 am\" data-tweet=\"$PULM $AST $OSUR - Healthcare - Top Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3252493-healthcare-top-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3252493-healthcare-top-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252489\" data-ts=\"1490108405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNCE\" target=\"_blank\">VNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252489-vince-holdingplus-12_7-after-tripping-volatility-breaker\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vince Holding +12.7% after tripping volatility breaker</a></h4><ul>   <li>Apparel designer Vince Holding Corp. (NYSE:<a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a>) has come out of a volatility halt <font color='green'>up 12.7%</font> after <font color='green'>spiking 43%</font>.</li>    <li>The moves are coming on heavy volume, with the bulk of the day's share moving in the past 10 minutes.</li>    <li>The stock is coming off a 52-week low re-set just yesterday (of $1.30).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252489\" data-linked=\"Vince Holding +12.7% after tripping volatility breaker\" data-tweet=\"$VNCE - Vince Holding +12.7% after tripping volatility breaker https://seekingalpha.com/news/3252489-vince-holdingplus-12_7-after-tripping-volatility-breaker?source=tweet\" data-url=\"https://seekingalpha.com/news/3252489-vince-holdingplus-12_7-after-tripping-volatility-breaker\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252488\" data-ts=\"1490108314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252488-biogen-up-1-on-favorable-patent-decision\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen up 1% on favorable patent decision</a></h4><ul><li>Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+1.2%</font>) perks up on modestly higher volume after the U.S. Patent Trial and Appeal Board upholds its '514 patent covering MS drug Tecfidera (dimethyl fumarate). A group led by Kyle Bass challenged the patent in an inter partes review proceeding.</li><li>Tecfidera is the company's top seller, generating almost $4B in sales over the past four quarters.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252488\" data-linked=\"Biogen up 1% on favorable patent decision\" data-tweet=\"$BIIB - Biogen up 1% on favorable patent decision https://seekingalpha.com/news/3252488-biogen-up-1-on-favorable-patent-decision?source=tweet\" data-url=\"https://seekingalpha.com/news/3252488-biogen-up-1-on-favorable-patent-decision\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252487\" data-ts=\"1490107978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252487-cheetah-mobileminus-7_6-after-downbeat-forecast-cfo-resigns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile -7.6% after downbeat forecast; CFO resigns</a></h4><ul>   <li>Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) is <font color='red'>7.6% lower</font>, taking some edge off a March run, following <a href=\"https://seekingalpha.com/news/3252392-cheetah-mobile-beats-cny0_34-beats-revenue\" target=\"_blank\">Q4 earnings</a> where it beat expectations but guided low for Q1 and noted its chief financial officer is exiting.</li>    <li>CFO Ka Wai Andy Yeung resigned effective March 31 to pursue other opportunities, and not due to any disagreement. Yuk Keung Francis Ng has been named interim CFO.</li>    <li>The company expects Q1 revenues of 1.15B-1.19B yuan, below consensus for 1.25B yuan. The company's forecast would be a Y/Y gain of 3-7%, but a drop Q/Q of 7-10%.</li>    <li>For Q4, revenues grew 11% to 1.275B yuan (about $183.6M). Mobile revenues (81.1% of total) came to 1.033B yuan, up 27.9% Y/Y.</li>    <li>Overseas revenues, meanwhile, made up 65.3% of total and grew 31.3% Y/Y to 832.6M yuan.</li>    <li>Global mobile monthly active users came to 623M, with overseas mobile MAUs making up 81% of the total.</li>    <li>The company's hit a total of 3.81B total global mobile user installations.</li>    <li><a href=\"https://seekingalpha.com/pr/16776469-cheetah-mobile-announces-fourth-quarter-fiscal-year-2016-unaudited-consolidated-financial\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252487\" data-linked=\"Cheetah Mobile -7.6% after downbeat forecast; CFO resigns\" data-tweet=\"$CMCM - Cheetah Mobile -7.6% after downbeat forecast; CFO resigns https://seekingalpha.com/news/3252487-cheetah-mobileminus-7_6-after-downbeat-forecast-cfo-resigns?source=tweet\" data-url=\"https://seekingalpha.com/news/3252487-cheetah-mobileminus-7_6-after-downbeat-forecast-cfo-resigns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252486\" data-ts=\"1490107971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEMP\" target=\"_blank\">GEMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252486-gemphires-gemcabene-shows-cardiometabolic-benefit-in-mid-stage-study-in-obese-patients-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gemphire&#39;s gemcabene shows cardiometabolic benefit in mid-stage study in obese patients; shares up 2%</a></h4><ul><li>Ultra-thinly traded micro cap Gemphire Therapeutics (<a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='green'>+2.4%</font>) perks up on almost double normal volume, albeit on turnover of only 26K shares, in response to its <a href=\"https://seekingalpha.com/pr/16776990-gemphire-therapeutics-announces-presentation-acc-meeting-phase-2-clinical-trial-investigating\" target=\"_blank\">announcement </a>of positive results in a Phase 2 clinical trial assessing gemcabene in non-diabetic obese patients. The data were presented at the American College of Cardiology 66th Annual Scientific Session in Washington, DC.</li><li>The study enrolled 53 patients with BMI 30 - 40kg/m2 (obese) with fasting glucose less than 126 mg/dL. Following a two-week screening phase, participants were randomized to receive either 900 mg of gemcabene or placebo on day 2 through week 4. The primary endpoint was insulin sensitivity as measured by quantified glucose disposal rate &#40;GDR&#41;.</li><li>Patients treated with gemcabene showed a 13% average increase in GDR compared to 6.8% for placebo. In addition, the gemcabene group experienced a 40% decrease in LDL-C (bad cholesterol) and a 27% decrease in total cholesterol.</li><li>The company plans to continue evaluating gemcabene for glycemic control and dyslipidemia in additional studies.</li><li>Orphan Drug-tagged gemcabene is a once-daily orally available medication for patients unable to achieve normal levels of LDL-C or triglycerides with currently available therapies. It&nbsp;has a dual&nbsp;<a href=\"http://www.gemphire.com/products-and-trials.php#a-differentiated-product-profile\" target=\"_blank\">mechanism of action</a>&nbsp;that blocks the production of hepatic triglyceride and cholesterol synthesis and enhances the clearance of VLDL (very low density lipoprotein). Specifically, it inhibits a liver protein called apolipoprotein C-III and may inhibit a liver enzyme called acetyl-CoA carboxylase.&nbsp;Gemphire licensed it from Pfizer in April 2011.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252486\" data-linked=\"Gemphire&#39;s gemcabene shows cardiometabolic benefit in mid-stage study in obese patients; shares up 2%\" data-tweet=\"$GEMP - Gemphire&#39;s gemcabene shows cardiometabolic benefit in mid-stage study in obese patients; shares up 2% https://seekingalpha.com/news/3252486-gemphires-gemcabene-shows-cardiometabolic-benefit-in-mid-stage-study-in-obese-patients-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3252486-gemphires-gemcabene-shows-cardiometabolic-benefit-in-mid-stage-study-in-obese-patients-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252483\" data-ts=\"1490107736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LE\" target=\"_blank\">LE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252483-on-lands-ends-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Lands&#39; End&#39;s Q4</a></h4><ul>     <li>Lands' End (<a href='https://seekingalpha.com/symbol/LE' title='Lands&#39; End, Inc.'>LE</a> <font color='red'>-0.3%</font>)&nbsp;reports direct segment revenue fell 2.6% to $398.5M in <a href=\"https://seekingalpha.com/pr/16776394-lands-end-announces-fourth-quarter-fiscal-2016-results\" target=\"_blank\">Q4</a>.</li>     <li>Retail segment revenue dropped 6.3% to $60.3M during the quarter.</li>     <li>Retail same-store sales squeezed 1.7%..</li>     <li>Gross margin rate slipped 340 bps to 38.6%.</li>     <li>SG&amp;A expenses rate flat at 31.9%.</li>     <li>Inventories -1.2% to $325.3M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252483\" data-linked=\"More on Lands&#39; End&#39;s Q4\" data-tweet=\"$LE - More on Lands&#39; End&#39;s Q4 https://seekingalpha.com/news/3252483-on-lands-ends-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3252483-on-lands-ends-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252484\" data-ts=\"1490107702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252484-canadian-solarminus-9-after-q4-miss-guides-q1-revenue-below-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar -9% after Q4 miss, guides Q1 revenue below consensus</a></h4><ul><li>Canadian Solar (<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-9.2%</font>) plunges more than 9% after missing expectations for both <a href=\"https://seekingalpha.com/news/3252391-canadian-solar-misses-0_08-misses-revenue\" target=\"_blank\">Q4 earnings</a> and revenues, and guiding Q1 revenues below consensus.</li><li>CSIQ says it expects Q1 revenues of $570M-$590M vs. $683M analyst consensus estimate, with gross margin of 13%-15%, and sees FY 2017 revenues of $4B-$5B vs. $3.36B consensus.</li><li>CSIQ says total solar module shipments set a record high at 1,612 MW, vs. guidance of 1,400-1,500 MW, of which 1,581 MW  were recognized in revenue, compared to  1,161 MW recognized in revenue in Q3.</li><li>For FY 2017, CSIQ expects total module shipments of 6.5-7 GW, with ~6.17 GW recognized  in revenue, and expects to connect 1-1.2 GW of new solar projects globally in 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252484\" data-linked=\"Canadian Solar -9% after Q4 miss, guides Q1 revenue below consensus\" data-tweet=\"$CSIQ - Canadian Solar -9% after Q4 miss, guides Q1 revenue below consensus https://seekingalpha.com/news/3252484-canadian-solarminus-9-after-q4-miss-guides-q1-revenue-below-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3252484-canadian-solarminus-9-after-q4-miss-guides-q1-revenue-below-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252481\" data-ts=\"1490106859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLY\" target=\"_blank\">ALLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252481-auto-names-tripped-up-allys-warning-on-used-car-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto names tripped up by Ally&#39;s warning on used car prices</a></h4><ul><li>Ally Financial (<a href='https://seekingalpha.com/symbol/ALLY' title='Ally Financial Inc.'>ALLY</a> <font color='red'>-0.1%</font>) earlier <a href=\"https://seekingalpha.com/news/3252417-ally-financial-talks-financial-outlook\" target=\"_blank\">guided to full-year</a> adjusted EPS growth coming in a little soft thanks to lease and used vehicle price declines (and provision build).</li><li><a href=\"https://www.ally.com/about/investor/events-presentations/\" target=\"_blank\">The presentation</a> noted a 7.1% Y/Y decline in the NADA index in Q1. Ally is seeing a 6.5% Y/Y fall.</li><li>AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color='red'>-2.2%</font>), Hertz (<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='red'>-5.7%</font>), Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color='red'>-3.5%</font>), CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a> <font color='red'>-1.6%</font>), Avis (<a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='red'>-6.9%</font>), Asbury Auto (<a href='https://seekingalpha.com/symbol/ABG' title='Asbury Automotive Group, Inc.'>ABG</a> <font color='red'>-1.3%</font>), Penske (<a href='https://seekingalpha.com/symbol/PAG' title='Penske Automotive Group, Inc.'>PAG</a> <font color='red'>-2.8%</font>), Group 1 (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color='red'>-3.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252481\" data-linked=\"Auto names tripped up by Ally&#39;s warning on used car prices\" data-tweet=\"$ALLY $ALLY $AN - Auto names tripped up by Ally&#39;s warning on used car prices https://seekingalpha.com/news/3252481-auto-names-tripped-up-allys-warning-on-used-car-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3252481-auto-names-tripped-up-allys-warning-on-used-car-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252480\" data-ts=\"1490106540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252480-synapticsminus-5_6-following-guidance-withdrawal-fingerprint-cards\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics -5.6% following guidance withdrawal at Fingerprint Cards</a></h4><ul><li><a href=\"https://www.fingerprints.com/\" target=\"_blank\">Fingerprint Cards</a>&nbsp;(<a href=\"https://seekingalpha.com/symbol/FGRPF/related\" target=\"_blank\">FGRPF</a>, <a href=\"https://seekingalpha.com/symbol/FGRRF/related\" target=\"_blank\">FGRRF</a>), a biometric operation based in Sweden, <a href=\"https://corporate.fingerprints.com/en/2017/03/21/fingerprint-cards-ab-expects-an-even-weaker-q1-and-the-short-term-challenges-to-prevail-in-q2/\" target=\"_blank\">notes</a> weak demand out of OEM customers in Q1, increasing channel inventory accumulation and expectation for persistence of issues near-term as it forecasts a revenue reduction of more than 50% Y/Y for the term, indicators weighing today on Synaptics trade.</li><li>Shares (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>)&nbsp;$48.61.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252480\" data-linked=\"Synaptics -5.6% following guidance withdrawal at Fingerprint Cards\" data-tweet=\"$SYNA $FGRPF $FGRRF - Synaptics -5.6% following guidance withdrawal at Fingerprint Cards https://seekingalpha.com/news/3252480-synapticsminus-5_6-following-guidance-withdrawal-fingerprint-cards?source=tweet\" data-url=\"https://seekingalpha.com/news/3252480-synapticsminus-5_6-following-guidance-withdrawal-fingerprint-cards\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252478\" data-ts=\"1490106473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252478-pulmatrix-nabs-european-patent-for-inhaled-drug-delivery-shares-ahead-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix nabs European patent for inhaled drug delivery; shares ahead 32%</a></h4><ul><li>Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+31.7%</font>) is up on increased volume in response to its announcement that it has been <a href=\"https://seekingalpha.com/pr/16777036-pulmatrix-receives-european-patent-inhaled-drug-delivery-technology\" target=\"_blank\">awarded a new patent</a> in the EU covering its drug delivery technology and its use in treating a range of diseases. The patent is similar to those already in place in the U.S. and Japan.</li><li>The company says its technology uses dry powders that 'fly' easily into the lungs, making the delivery much more efficient. In addition, the technology can deliver much larger doses of drugs&mdash;and many more different types of drugs&mdash;than existing methods can.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252478\" data-linked=\"Pulmatrix nabs European patent for inhaled drug delivery; shares ahead 32%\" data-tweet=\"$PULM - Pulmatrix nabs European patent for inhaled drug delivery; shares ahead 32% https://seekingalpha.com/news/3252478-pulmatrix-nabs-european-patent-for-inhaled-drug-delivery-shares-ahead-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3252478-pulmatrix-nabs-european-patent-for-inhaled-drug-delivery-shares-ahead-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252476\" data-ts=\"1490106188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDC\" target=\"_blank\">DDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252476-reuters-dominion-diamond-stornoway-held-merger-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Dominion Diamond, Stornoway held merger talks</a></h4><ul>     <li>Dominion Diamond (<a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+2.5%</font>) and smaller Canadian diamond miner Stornoway Diamond (<a href='https://seekingalpha.com/symbol/SWYDF' title='Stornoway Diamond Corp.'>OTCPK:SWYDF</a> <font color='green'>+3.9%</font>) have <a href=\"http://www.reuters.com/article/us-dominion-diamond-m-a-stornoway-diamon-idUSKBN16R2QJ\" target=\"_blank\">held talks about a potential merger</a> in recent months, Reuters reports.</li>     <li>The talks include Stornoway's CEO and president, Matt Manson, becoming CEO of the merged group, with the discussions on an all-share merger beginning in January, according to the report.</li>     <li>DDC, which owns the Ekati diamond mine in Canada's Northwest Territories and a 40% stake in the nearby Diavik mine, is looking for a new CEO after announcing in January that Brendan Bell had resigned.</li>     <li><a href=\"https://seekingalpha.com/news/3252120-washington-cos-makes-move-dominion-diamond\" target=\"_blank\">Earlier this week</a>, The Washington Cos. said it had made a $1.1B takeover proposal for DDC.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252476\" data-linked=\"Reuters: Dominion Diamond, Stornoway held merger talks\" data-tweet=\"$DDC $DDC $SWYDF - Reuters: Dominion Diamond, Stornoway held merger talks https://seekingalpha.com/news/3252476-reuters-dominion-diamond-stornoway-held-merger-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3252476-reuters-dominion-diamond-stornoway-held-merger-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252475\" data-ts=\"1490105972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252475-intelsatplus-4_5-extends-media-deals-in-africa-russia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat +4.5% as it extends media deals in Africa, Russia</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) is <font color='green'>up 4.5%</font> today and hitting its highest point this month after a pair of deals expanding media distribution relationships.</li>    <li>The company and Sentech have expanded an existing relationship to boost delivery of <a href=\"https://seekingalpha.com/pr/16776250-intelsat-sentech-expand-media-distribution-relationship-intelsat-20-satellite-deliver-content\" target=\"_blank\">media service in sub-Saharan Africa</a>. The two have been partners for decades and Sentech has distributed its signal to 8.5M TV households.</li>    <li>In the deal, Sentech has contracted additional services on Intelsat 20.</li>    <li>Meanwhile, Orion Express signed a <a href=\"https://seekingalpha.com/pr/16776251-intelsat-orion-express-extend-agreement-deliver-media-services-across-russia-using-intelsat\" target=\"_blank\">multi-year extension</a> for media distribution in Russia, using Intelsat 15. The new deal will cement that use \"well into the next decade\" and further consolidates services with Intelsat from another operator.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252475\" data-linked=\"Intelsat +4.5% as it extends media deals in Africa, Russia\" data-tweet=\"$I - Intelsat +4.5% as it extends media deals in Africa, Russia https://seekingalpha.com/news/3252475-intelsatplus-4_5-extends-media-deals-in-africa-russia?source=tweet\" data-url=\"https://seekingalpha.com/news/3252475-intelsatplus-4_5-extends-media-deals-in-africa-russia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252473\" data-ts=\"1490105929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252473-losses-for-kohls-macys-on-q1-caution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More losses for Kohl&#39;s, Macy&#39;s on Q1 caution</a></h4><ul><li>Cleveland Research's Scott Bender says Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-2.3%</font>) Q1-to-date comps look to be trending below estimates, with weather headwinds and tight inventory among the issues.</li><li>Again noting the weather, he says Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-2.1%</font>) is looking \"slightly softer,\" but the company could still hit Q1 consensus in part thanks to easier Y/Y comps.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3252473\" data-linked=\"More losses for Kohl&#39;s, Macy&#39;s on Q1 caution\" data-tweet=\"$KSS $KSS $M - More losses for Kohl&#39;s, Macy&#39;s on Q1 caution https://seekingalpha.com/news/3252473-losses-for-kohls-macys-on-q1-caution?source=tweet\" data-url=\"https://seekingalpha.com/news/3252473-losses-for-kohls-macys-on-q1-caution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252472\" data-ts=\"1490105831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252472-axsome-prices-equity-offering-shares-down-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome prices equity offering; shares down 17%</a></h4><ul><li>Axsome Therapeutics (<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a> <font color='red'>-17%</font>) <a href=\"https://seekingalpha.com/pr/16776998-axsome-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 3,743,316 shares of common stock at $3.74. Underwriters over-allotment is an additional 561,497 shares. Closing date is March 24.</li><li>Yesterday's close was $4.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252472\" data-linked=\"Axsome prices equity offering; shares down 17%\" data-tweet=\"$AXSM - Axsome prices equity offering; shares down 17% https://seekingalpha.com/news/3252472-axsome-prices-equity-offering-shares-down-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3252472-axsome-prices-equity-offering-shares-down-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252470\" data-ts=\"1490105603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252470-gnc-perky-on-report-of-chinese-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC perky on report of more Chinese interest</a></h4><ul><li>According to Dealreporter, JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a>) has joined the likes of KKR, Fosun Group, ZZ Capital and others with interest in acquiring GNC Holdings (<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+2.7%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3252470\" data-linked=\"GNC perky on report of more Chinese interest\" data-tweet=\"$JD $JD $GNC - GNC perky on report of more Chinese interest https://seekingalpha.com/news/3252470-gnc-perky-on-report-of-chinese-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3252470-gnc-perky-on-report-of-chinese-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252467\" data-ts=\"1490105550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AST\" target=\"_blank\">AST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252467-asterias-bios-cell-therapy-continues-to-demonstrate-treatment-effect-in-spinal-cord-injury\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asterias Bio&#39;s cell therapy continues to demonstrate treatment effect in spinal cord injury patients; shares ahead 12%</a></h4><ul><li>Thinly traded micro cap Asterias Biotherapeutics (<a href='https://seekingalpha.com/symbol/AST' title='Asterias Biotherapeutics, Inc.'>AST</a> <font color='green'>+12.4%</font>) perks up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16776424-update-full-six-patient-cohort-confirms-patients-complete-paralysis-can-experience-meaningful\" target=\"_blank\">update </a>on its ongoing SciStar Phase 1/2a clinical trial assessing the 10M-cell dose of AST-OPC1 (oligodendrocyte progenitor cells) in patients with sub-acute C-5 to C-7 cervical spinal cord injury &#40;SCI&#41;.</li><li>Data on the sixth and final patient in the AIS-A (complete injury, no motor function below the injury site) 10M cell cohort showed upper extremity motor function improvement at month 3 and further improvement in month 6. The results were consistent with the five previous patients. Upper extremity motor function is the most desirable functional improvement in the quadriplegic population.</li><li>CEO Steve Cartt says, \"These results are quite encouraging, and suggest that there are meaningful improvements in the recovery of functional ability in patients treated with the 10 million cell dose of AST-OPC1 versus spontaneous recovery rates observed in a closely matched untreated patient population. We look forward to reporting additional efficacy and safety data for this cohort, as well as for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, later this year.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3252467\" data-linked=\"Asterias Bio&#39;s cell therapy continues to demonstrate treatment effect in spinal cord injury patients; shares ahead 12%\" data-tweet=\"$AST - Asterias Bio&#39;s cell therapy continues to demonstrate treatment effect in spinal cord injury patients; shares ahead 12% https://seekingalpha.com/news/3252467-asterias-bios-cell-therapy-continues-to-demonstrate-treatment-effect-in-spinal-cord-injury?source=tweet\" data-url=\"https://seekingalpha.com/news/3252467-asterias-bios-cell-therapy-continues-to-demonstrate-treatment-effect-in-spinal-cord-injury\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252469\" data-ts=\"1490105283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSI\" target=\"_blank\">MSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252469-motorola-solutionsplus-1_8-jefferies-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Motorola Solutions +1.8% as Jefferies upgrades to Buy</a></h4><ul>   <li>Motorola Solutions (NYSE:<a href='https://seekingalpha.com/symbol/MSI' title='Motorola Solutions, Inc.'>MSI</a>) is <font color='green'>up 1.8%</font> in early going after Jefferies upgraded shares to Buy, suggesting other analysts are taking too dim a view on earnings.</li>    <li>There's upside to consensus EPS expectations, writes analyst George Notter, from tax and interest assumptions as well as the company's <a href=\"https://seekingalpha.com/news/3250727-motorola-solutions-acquires-chiles-interexport\" target=\"_blank\">acquisition of Interexport</a> to build managed and support services in Latin America.</li><li>He's boosted full-year estimates to $5.40 from $5.10, according to Bloomberg.</li>    <li>Jefferies boosted its price target on MSI to $100 from $75, implying 16.5% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252469\" data-linked=\"Motorola Solutions +1.8% as Jefferies upgrades to Buy\" data-tweet=\"$MSI - Motorola Solutions +1.8% as Jefferies upgrades to Buy https://seekingalpha.com/news/3252469-motorola-solutionsplus-1_8-jefferies-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3252469-motorola-solutionsplus-1_8-jefferies-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252466\" data-ts=\"1490104987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252466-chipotle-up-nearly-3-on-report-of-strong-march\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle up nearly 3% on report of strong March</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>M Science is out with a note saying March comps have accelerated markedly at Chipotle (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='green'>+2.7%</font>). The team there thinks Q1 same-store sales growth will easily top expectations of 14.9%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252466\" data-linked=\"Chipotle up nearly 3% on report of strong March\" data-tweet=\"$CMG - Chipotle up nearly 3% on report of strong March https://seekingalpha.com/news/3252466-chipotle-up-nearly-3-on-report-of-strong-march?source=tweet\" data-url=\"https://seekingalpha.com/news/3252466-chipotle-up-nearly-3-on-report-of-strong-march\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252461\" data-ts=\"1490104423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252461-shopify-raised-to-75-target-btig\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify raised to $75 target at BTIG</a></h4><ul><li>Reiterating Buy, <a href=\"http://www.streetinsider.com/Analyst+Comments/Shopify+%28SHOP%29+PT+Raised+to+%2475+at+BTIG%3B+Reiterates+Buy/12690136.html\" target=\"_blank\">analyst Abhinav Kapur</a> considers strong share performance over the last year (<font color='green'>150%+</font>) to represent outcome of a product striking balance with its market, rather than irrational ebullience. Expects growth trajectory to sustain. Target from $65.</li><li>Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify'>SHOP</a>) $70.54,&nbsp;<font color='green'>+2.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252461\" data-linked=\"Shopify raised to $75 target at BTIG\" data-tweet=\"$SHOP - Shopify raised to $75 target at BTIG https://seekingalpha.com/news/3252461-shopify-raised-to-75-target-btig?source=tweet\" data-url=\"https://seekingalpha.com/news/3252461-shopify-raised-to-75-target-btig\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252458\" data-ts=\"1490103789\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252458-freeport-teck-upgraded-deutsche-bank-in-improved-commodities-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport, Teck upgraded at Deutsche Bank in improved commodities view</a></h4><ul><li>Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='green'>+3%</font>) and Teck Resources (<a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='green'>+2.7%</font>) open higher after meriting <a href=\"http://www.insidermonkey.com/blog/heres-why-goldman-sachs-rite-aid-teck-resources-freeport-mcmoran-and-more-are-in-the-spotlight-567862/?singlepage=1\" target=\"_blank\">upgrades</a> from Deutsche Bank, part of a more positive outlook for industrial commodities that the firm says could boost free cash flow for select miners.</li><li>FCX is upgraded to Hold from Sell with a $14 price target, up from $12.50, and TECK is hiked to Buy from Hold with a $25 target, lifted by $1, as Deutsche Bank raises its price estimates for copper, zinc and iron ore due to stronger demand from the Chinese infrastructure and  property market.</li><li>DB's Buy-rated industrial metal equities are TECK, <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> and  <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a>; the firm's Buy-rated precious metals stocks are <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a>, ABX, SLW and <a href='https://seekingalpha.com/symbol/PAAS' title='Pan American Silver Corp.'>PAAS</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252458\" data-linked=\"Freeport, Teck upgraded at Deutsche Bank in improved commodities view\" data-tweet=\"$FCX $FCX $TECK - Freeport, Teck upgraded at Deutsche Bank in improved commodities view https://seekingalpha.com/news/3252458-freeport-teck-upgraded-deutsche-bank-in-improved-commodities-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3252458-freeport-teck-upgraded-deutsche-bank-in-improved-commodities-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252457\" data-ts=\"1490103659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBIX\" target=\"_blank\">NBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252457-neurocrine-bios-ingrezza-shows-treatment-benefit-in-involuntary-movement-disorder-in-late\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neurocrine Bio&#39;s Ingrezza shows treatment benefit in involuntary movement disorder in late-stage study; shares ahead 2%</a></h4><ul><li>A Phase 3 clinical trial, Kinect 3, assessing Neurocrine Biosciences' (<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color='green'>+1.6%</font>) INGREZZA (valbenazine) for the treatment of tardive dyskinesia &#40;TD&#41; <a href=\"https://seekingalpha.com/pr/16776802-neurocrine-announces-american-journal-psychiatry-publication-positive-results-kinect-3-phase\" target=\"_blank\">met its primary endpoint</a> of a statistically valid change from baseline in a scale called AIMS compared to placebo (p&lt;0.0001). The <a href=\"http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2017.16091037?journalCode=ajp\" target=\"_blank\">results were published online</a> by the <em>American Journal of Psychiatry</em>.</li><li>The company's U.S. marketing application is currently under FDA review with an action date &#40;PDUFA&#41; of April 11.</li><li>Valbenazine inhibits a protein called Vesicular Monoamine Transporter 2 (<a href=\"https://en.wikipedia.org/wiki/Vesicular_monoamine_transporter_2\" target=\"_blank\">VMAT2</a>), which is concentrated in the brain where it plays a key role in the re-packaging and transporting of monoamines (dopamine, norepinephrine, serotonin and histamine) in certain neurons. It modulates dopamine release during nerve communication while exerting minimal impact on other monoamines, thereby minimizing unwanted side effects associated with excessive monoamine depletion.&nbsp;Modulating dopamine levels has shown to deliver positive treatment effects in patients with Tourette, Huntington's chorea, tardive dyskinesia and schizophrenia.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3213295-neurocrines-ingrezza-nda-involuntary-movement-disorder-accepted-priority-review-fda-action\" target=\"_blank\">Neurocrine's Ingrezza NDA for involuntary movement disorder accepted under Priority Review by FDA, action date April 11</a> (Oct. 11, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252457\" data-linked=\"Neurocrine Bio&#39;s Ingrezza shows treatment benefit in involuntary movement disorder in late-stage study; shares ahead 2%\" data-tweet=\"$NBIX - Neurocrine Bio&#39;s Ingrezza shows treatment benefit in involuntary movement disorder in late-stage study; shares ahead 2% https://seekingalpha.com/news/3252457-neurocrine-bios-ingrezza-shows-treatment-benefit-in-involuntary-movement-disorder-in-late?source=tweet\" data-url=\"https://seekingalpha.com/news/3252457-neurocrine-bios-ingrezza-shows-treatment-benefit-in-involuntary-movement-disorder-in-late\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252455\" data-ts=\"1490103526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252455-kate-spade-final-bid-unlikely-to-be-premium-dealreporter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kate Spade final bid unlikely to be at premium - DealReporter</a></h4><ul><li>Final bids are coming next week, according to the report, with Michael Kors (KORS) and Coach (COH) among those still interested.</li><li><a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a> isn't likely to see a bid any higher than the current valuation, though that's still 40-50% more than the stock price in December ahead of reports the company was up for sale.</li><li>KATE&nbsp;<font color='red'>-3.75%</font>&nbsp;to $22.84.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252455\" data-linked=\"Kate Spade final bid unlikely to be at premium - DealReporter\" data-tweet=\"$CPRI $CPRI $TPR - Kate Spade final bid unlikely to be at premium - DealReporter https://seekingalpha.com/news/3252455-kate-spade-final-bid-unlikely-to-be-premium-dealreporter?source=tweet\" data-url=\"https://seekingalpha.com/news/3252455-kate-spade-final-bid-unlikely-to-be-premium-dealreporter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252446\" data-ts=\"1490102801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SILC\" target=\"_blank\">SILC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252446-silicomplus-18_9-touts-design-win-from-cloud-player\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silicom +18.9% as it touts design win from cloud player</a></h4><ul>   <li>Israel's Silicom (NASDAQ:<a href='https://seekingalpha.com/symbol/SILC' title='Silicom Ltd'>SILC</a>) is <font color='green'>up 18.9%</font> premarket after noting the \"<a href=\"https://seekingalpha.com/pr/16776651-breakthrough-success-silicom-major-new-design-win-17m-orders-hand-projected-annual-sales-30m\" target=\"_blank\">most significant design win</a> in its history,\" from what it says is a top 10 cloud player.</li>    <li>The company expects revenues to build to $30M a year for a highly customized version of its 100 Gb high-bandwidth switch fabric. It's gotten $17M in initial purchase orders in the deal, to get the product from alpha to first commercial deployment.</li>    <li>Silicom's now delivering beta program products in the deal. There are still \"challenges\" to overcome before large-scale data center deployment, says CEO Shaike Orbach, but they're on the right track and \"our customer shares this view, as demonstrated by these sizeable initial purchase orders and its close, enthusiastic cooperation in the project.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252446\" data-linked=\"Silicom +18.9% as it touts design win from cloud player\" data-tweet=\"$SILC - Silicom +18.9% as it touts design win from cloud player https://seekingalpha.com/news/3252446-silicomplus-18_9-touts-design-win-from-cloud-player?source=tweet\" data-url=\"https://seekingalpha.com/news/3252446-silicomplus-18_9-touts-design-win-from-cloud-player\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252443\" data-ts=\"1490102659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252443-premarket-gainers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:10 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/VSR' title='Versar, Inc'>VSR</a> <font color='green'>+40%</font>.</li><li><a href='https://seekingalpha.com/symbol/ATNM' title='Actinium Pharmaceuticals, Inc.'>ATNM</a> <font color='green'>+17%</font> on receipt of positive scientific advice for Iomab-B.</li><li><a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a> <font color='green'>+11%</font> on Q4 earnings beat.</li><li><a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='green'>+7%</font> on strategic agreement with POSCO Energy.</li><li><a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='green'>+7%</font> on analyst upgrade.</li><li><a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+5%</font> on closing $173M equity offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3252443\" data-linked=\"Premarket Gainers as of 9:10 am\" data-tweet=\"$VSR $ATNM $FRAN - Premarket Gainers as of 9:10 am https://seekingalpha.com/news/3252443-premarket-gainers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3252443-premarket-gainers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252442\" data-ts=\"1490102640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNM\" target=\"_blank\">ATNM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252442-ema-says-actinium-pharmas-late-stage-iomab-b-study-sufficient-for-marketing-application-in-eu\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA says Actinium Pharma&#39;s late-stage Iomab-B study sufficient for marketing application in EU; shares ahead 17% premarket</a></h4><ul><li>Nano cap Actinium Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/ATNM' title='Actinium Pharmaceuticals, Inc.'>ATNM</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16776450-actinium-announces-receipt-positive-scientific-advice-european-medicines-agency-iomab-b\" target=\"_blank\">announcement </a>that it has received positive guidance (Scientific Advice) from the European Medicines Agency &#40;EMA&#41; regarding its late-stage trial design and statistical analysis plan for lead product candidate Iomab-B in acute myeloid leukemia &#40;AML&#41;.</li><li>In a letter to the company, the EMA stated that its Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02665065?term=iomab-b&amp;phase=2&amp;rank=1\" target=\"_blank\">SIERRA </a>study and statistical approach are acceptable and can serve as the basis for submitting a Marketing Authorization Application &#40;MAA&#41;. The EMA added that it does not anticipate needing additional preclinical toxicology or safety studies. According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint of durable complete response is April 2018.</li><li>If approved, Iomab-B will be used as an induction and conditioning agent prior to bone marrow transplant in patients with relapsed/refractory AML who are at least 55 years old.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252442\" data-linked=\"EMA says Actinium Pharma&#39;s late-stage Iomab-B study sufficient for marketing application in EU; shares ahead 17% premarket\" data-tweet=\"$ATNM - EMA says Actinium Pharma&#39;s late-stage Iomab-B study sufficient for marketing application in EU; shares ahead 17% premarket https://seekingalpha.com/news/3252442-ema-says-actinium-pharmas-late-stage-iomab-b-study-sufficient-for-marketing-application-in-eu?source=tweet\" data-url=\"https://seekingalpha.com/news/3252442-ema-says-actinium-pharmas-late-stage-iomab-b-study-sufficient-for-marketing-application-in-eu\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252445\" data-ts=\"1490102403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252445-premarket-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:10 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a> <font color='red'>-16%</font> on secondary offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3252445\" data-linked=\"Premarket Losers as of 9:10 am\" data-tweet=\"$AXSM - Premarket Losers as of 9:10 am https://seekingalpha.com/news/3252445-premarket-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3252445-premarket-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252438\" data-ts=\"1490102064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESPR\" target=\"_blank\">ESPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252438-esperion-therapeutics-up-another-7-citi-doubles-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Esperion Therapeutics up another 7%; Citi doubles price target</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls/status/844173417389735937\" target=\"_blank\">via Notable Calls</a></li><li>Investors haven't fully priced in this announcement, says Citigroup, raising its price target on Esperion (NASDAQ:<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a>) to $77 from $38, suggesting more than&nbsp;<font color='green'>85% upside</font>&nbsp;from yesterday's close.</li><li>Shares<font color='green'> +7.1%</font>&nbsp;premarket to $44.15.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252194-fda-board-esperions-late-stage-development-program-bad-cholesterol-lowering-claim-bempedoic\" target=\"_blank\">FDA on board with Esperion's late-stage development program for bad cholesterol-lowering claim for bempedoic acid; shares ahead 33% premarket</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252438\" data-linked=\"Esperion Therapeutics up another 7%; Citi doubles price target\" data-tweet=\"$ESPR - Esperion Therapeutics up another 7%; Citi doubles price target https://seekingalpha.com/news/3252438-esperion-therapeutics-up-another-7-citi-doubles-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3252438-esperion-therapeutics-up-another-7-citi-doubles-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252427\" data-ts=\"1490100553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTBX\" target=\"_blank\">HTBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252427-heat-bios-hsminus-110-shows-treatment-effect-in-mid-stage-lung-cancer-study-shares-ahead-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heat Bio&#39;s HS-110 shows treatment effect in mid-stage lung cancer study; shares ahead 16% premarket</a></h4><ul><li>Nano cap Heat Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a>) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16776447-heat-biologics-reports-positive-interim-phase-2-lung-cancer-results-patients-treated-hsminus\" target=\"_blank\">announcement </a>of positive preliminary results from a Phase 2 clinical trial assessing the combination of therapeutic vaccine candidate HS-110 (Viagenpumatucel-L) and Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of non-small cell lung cancer &#40;NSCLC&#41;.</li><li>15 patients completed treatment to date, 12 evaluable for <a href=\"https://en.wikipedia.org/wiki/ELISPOT\" target=\"_blank\">ELISPOT </a>analysis (an immunoassay used to monitor cellular immune responses). Five (42%) patients experienced tumor reductions and all five (100%) showed immune responses to HS-110. No tumor reductions were observed in patients that did not mount an immune response to HS-110.</li><li>Five patients have been enrolled in the low tumor infiltrating lymphocytes &#40;TIL&#41; cohort (patients with \"cold\" tumors). Three (60%) have shown significant tumor reduction, substantially better than the 10% response rate for nivolumab alone in low TIL patients.</li><li><a href=\"http://www.heatbio.com/product-pipeline/hs-110\" target=\"_blank\">HS-110</a>&nbsp;utilizes modified lung cancer cells to stimulate a patient's immune system to attack the cancer. The modification process is based on the company's&nbsp;<a href=\"http://www.heatbio.com/our-science/overview\" target=\"_blank\">ImPact&nbsp;</a>(Immune Pan-Antigen Cytotoxic Therapy) technology, an engineered cell line designed to express a version of a naturally occurring heat-shock protein called gp96, a very potent mammalian adjuvant.&nbsp;ImPact&nbsp;transforms cancer cells into miniature osmotic pumps that continually secrete gp96.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2755066-heat-bio-bags-mid-stage-trial-hsminus-110-favor-early-stage-combo-study-opdivo\" target=\"_blank\">Heat Bio bags mid-stage trial of HS-110 in favor of early-stage combo study with Opdivo</a> (Sept. 1, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252427\" data-linked=\"Heat Bio&#39;s HS-110 shows treatment effect in mid-stage lung cancer study; shares ahead 16% premarket\" data-tweet=\"$HTBX - Heat Bio&#39;s HS-110 shows treatment effect in mid-stage lung cancer study; shares ahead 16% premarket https://seekingalpha.com/news/3252427-heat-bios-hsminus-110-shows-treatment-effect-in-mid-stage-lung-cancer-study-shares-ahead-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3252427-heat-bios-hsminus-110-shows-treatment-effect-in-mid-stage-lung-cancer-study-shares-ahead-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252422\" data-ts=\"1490099292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRAN\" target=\"_blank\">FRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252422-francescas-higher-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Francesca&#39;s higher on earnings beat</a></h4><ul>     <li>Francesca's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>)&nbsp;reports sales rose 9% in <a href=\"https://seekingalpha.com/pr/16776493-francesca-s-exceeds-previous-guidance-full-year-eps-1_09-20-percent-increase-versus-prior\" target=\"_blank\">Q4</a> due to the addition of 55 net new boutiques Y/Y and a 42% increase in ecommerce sales driven by increased website traffic and conversion rate.</li>     <li>Merchandise category sales:&nbsp;Apparel: $60.68M (+14%); Jewelry: $34.07M (+15%);&nbsp;Accessories: $24.87M (+2%);&nbsp;Gifts: $25.83M (-3%).</li>     <li>Gross margin rate decreased 270 bps to 46.4%.</li>     <li>SG&amp;A expense rate down 90 bps to 30.3%.</li>     <li>Operating margin rate down 190 bps to 16.1%.</li>     <li>Inventory -24% Y/Y to $23.96M.</li>     <li>Boutique count +55 Y/Y to 671.</li>     <li><b>Q1 Guidance</b>:&nbsp;Net sales: $111M to $114M; Comparable-store sales: Low&nbsp;single digit decrease to flat range; EPS:&nbsp;$0.12 to $0.16.</li>     <li><b>FY2017 Guidance</b>: Net sales: $527M to $543M;&nbsp;Comparable-store sales: Flat to low-single digit increase;&nbsp;EPS: $1.11 to $1.21; Shares outstanding: 37.4M; Tax&nbsp;rate: 38%;&nbsp;Capital expenditure: $28M to $33M; New boutiques: ~60 to 65.</li>     <li>FRAN&nbsp;<font color='green'>+5.92%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252422\" data-linked=\"Francesca&#39;s higher on earnings beat\" data-tweet=\"$FRAN - Francesca&#39;s higher on earnings beat https://seekingalpha.com/news/3252422-francescas-higher-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3252422-francescas-higher-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252423\" data-ts=\"1490099224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252423-carnivalplus-1-on-william-blair-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival +1% on William Blair upgrade</a></h4><ul><li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>) has been <a href=\"https://www.streetinsider.com/Analyst+Comments/William+Blair+Upgrades+Carnival+Corporation+to+Outperform/12688874.html\" target=\"_blank\">raised</a> to Outperform from Market Perform at William Blair.</li><li>The firm said the cruise line operator is in a position to beat consensus earnings estimates, citing benefits from strong pricing in Europe, and favorable trends will continue into 2018.</li><li>CCL <font color='green'>+1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3252423\" data-linked=\"Carnival +1% on William Blair upgrade\" data-tweet=\"$CCL - Carnival +1% on William Blair upgrade https://seekingalpha.com/news/3252423-carnivalplus-1-on-william-blair-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3252423-carnivalplus-1-on-william-blair-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252416\" data-ts=\"1490098472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNST\" target=\"_blank\">MNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252416-food-stocks-in-focus-after-latest-research\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Food stocks in focus after latest research</a></h4><ul><li>Monster Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a>) <font color='green'>+1%</font>, Constellation Brands (NYSE:<a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a>), PepsiCo <font color='green'>+0.75%</font> premarket after JPMorgan initiated coverage with Overweight ratings.</li><li>Among the positive factors: Monster's expanding use of Coca-Cola's distribution system, PepsiCo's growth in snacks and non-carbonated beverages, and Constellation's fast growth and valuation.</li><li>Other food names are also on the move: ConAgra (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>) <font color='red'>-4.7%</font>, Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>) <font color='green'>+1.7%</font>, General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>) <font color='red'>-2.1%</font>, Kellogg (NYSE:<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a>) <font color='red'>-0.3%</font>, J.M. Smucker (NYSE:<a href='https://seekingalpha.com/symbol/SJM' title='J. M. Smucker Company'>SJM</a>) <font color='red'>-1.5%</font> following a Bernstein report that downgraded the firms to Underperform from Market Perform, citing weaker industry trends.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252416\" data-linked=\"Food stocks in focus after latest research\" data-tweet=\"$MNST $MNST $STZ - Food stocks in focus after latest research https://seekingalpha.com/news/3252416-food-stocks-in-focus-after-latest-research?source=tweet\" data-url=\"https://seekingalpha.com/news/3252416-food-stocks-in-focus-after-latest-research\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252412\" data-ts=\"1490097756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBSS\" target=\"_blank\">JBSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252412-john-b-sanfilippo-son-orasure-jump-on-moves-to-s-and-p-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">John B. Sanfilippo &amp; Son, OraSure jump on moves to S&amp;P SmallCap 600</a></h4><ul><li>John B. Sanfilippo &amp; Son (NASDAQ:<a href='https://seekingalpha.com/symbol/JBSS' title='John B. Sanfilippo & Son, Inc.'>JBSS</a>) will replace Popeyes ahead of the open on March 27. Shares&nbsp;<font color='green'>+3.7%</font>&nbsp;premarket.</li><li>Also on the move is OraSure Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/OSUR' title='OraSure Technologies, Inc.'>OSUR</a>),&nbsp;<font color='green'>+7.45%</font>&nbsp;as it will replace G&amp;K Services on March 23.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252412\" data-linked=\"John B. Sanfilippo &amp; Son, OraSure jump on moves to S&amp;P SmallCap 600\" data-tweet=\"$JBSS $JBSS $OSUR - John B. Sanfilippo &amp; Son, OraSure jump on moves to S&amp;P SmallCap 600 https://seekingalpha.com/news/3252412-john-b-sanfilippo-son-orasure-jump-on-moves-to-s-and-p-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3252412-john-b-sanfilippo-son-orasure-jump-on-moves-to-s-and-p-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252401\" data-ts=\"1490096568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIS\" target=\"_blank\">GIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252401-general-mills-lower-post-fq3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Mills lower post FQ3 results</a></h4><ul>     <li>General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>) reports organic &nbsp;net sales declined 5% in <a href=\"https://seekingalpha.com/pr/16776399-general-mills-reports-fiscal-2017-third-quarter-results\" target=\"_blank\">FQ3</a>, reflecting volume reductions in the North America Retail segment.</li>     <li>North America Retail sales decreased 7% to $2.5B and operating profit -7% to $517M.</li>     <li>Convenience Stores and Foodservice sales dropped 1% to $448M and operating profit +3% to $94M.</li>     <li>Adjusted gross margin rate grew 20 bps to 35%.</li>     <li>SG&amp;A expense rate down 80 bps to 18.1%.</li>     <li>Adjusted operating margin rate improved 100 bps to 16.9%.</li>     <li><b>FY2017 Guidance</b>: Organic net sales: ~-4%%&nbsp;; Adjusted operating margin: ~+120 bps;&nbsp;Adjusted EPS:&nbsp;+5% to +7% (on a constant currency basis).</li>     <li>GIS&nbsp;<font color='red'>-1.26%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252401\" data-linked=\"General Mills lower post FQ3 results\" data-tweet=\"$GIS - General Mills lower post FQ3 results https://seekingalpha.com/news/3252401-general-mills-lower-post-fq3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3252401-general-mills-lower-post-fq3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252393\" data-ts=\"1490095586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTIE\" target=\"_blank\">PTIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252393-pain-therapeutics-sets-path-for-resubmitting-nda-for-pain-med-remoxy-er-shares-up-65\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarket</a></h4><ul><li>Nano cap Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>) jumps&nbsp;<font color='green'>65%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16776218-pain-therapeutics-announces-positive-regulatory-guidance-remoxy-er\" target=\"_blank\">announcement </a>that it has received feedback from the FDA regarding the additional studies needed to refile its New Drug Application &#40;NDA&#41; seeking approval of abuse-deterrent REMOXY ER (extended-release oxycodone capsules CII).</li><li>The company says it will need to conduct two additional studies, a clinical abuse potential study assessing the intranasal route of abuse and a non-clinical abuse potential study using household solvents. It believes it can complete both by year-end at a cost of $3 - 4M.</li><li>Afterward, it plans to conduct a pre-NDA meeting with the agency and then resubmit its NDA under Priority Review via the 505(b)(2) pathway.</li><li>In September 2016, the company received a CRL in response to its marketing application, the third such rejection.</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the developments.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3210703-fda-rejects-pain-therapeutics-remoxy-er-marketing-application-shares-plummet-67-percent\" target=\"_blank\">FDA rejects Pain Therapeutics' Remoxy ER marketing application; shares plummet 67% premarket</a> (Sept. 26, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252393\" data-linked=\"Pain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarket\" data-tweet=\"$PTIE $SAVA - Pain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarket https://seekingalpha.com/news/3252393-pain-therapeutics-sets-path-for-resubmitting-nda-for-pain-med-remoxy-er-shares-up-65?source=tweet\" data-url=\"https://seekingalpha.com/news/3252393-pain-therapeutics-sets-path-for-resubmitting-nda-for-pain-med-remoxy-er-shares-up-65\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252392\" data-ts=\"1490095520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252392-cheetah-mobile-beats-cny0_34-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile beats by CNY0.34, beats on revenue</a></h4><ul><li>Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>): Q4 EPS of CNY0.80 <font color='green'>beats by CNY0.34</font>.</li><li>Revenue of CNY1.27B (+10.4% Y/Y) <font color='green'>beats by CNY140M</font>.</li><li>Shares <font color='green'>+4.9%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16776469-cheetah-mobile-announces-fourth-quarter-fiscal-year-2016-unaudited-consolidated-financial\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252392\" data-linked=\"Cheetah Mobile beats by CNY0.34, beats on revenue\" data-tweet=\"$CMCM - Cheetah Mobile beats by CNY0.34, beats on revenue https://seekingalpha.com/news/3252392-cheetah-mobile-beats-cny0_34-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3252392-cheetah-mobile-beats-cny0_34-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252388\" data-ts=\"1490094569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252388-valeants-offer-to-repurchase-1_1b-of-6_75-senior-debt-oversubscribed-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant&#39;s offer to repurchase $1.1B of 6.75% senior debt oversubscribed; shares up 1% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) <a href=\"https://seekingalpha.com/pr/16776248-valeant-announces-early-results-tender-offers-6_75-percent-senior-notes-due-2018\" target=\"_blank\">announces </a>that holders of its 6.75% Senior Notes due 2018 have validly tendered ~$1.55B of the debt in connection to its offer to repurchase for cash up to $1.1B. Since the offer is oversubscribed, it will prorate the purchases at 70.9%. Total consideration of $1,029.06 for each $1,000 principal amount of the Notes, plus accrued and unpaid interest, should be paid today.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3250282-valeant-upsizes-debt-offering-3_25b-shares-ahead-3-percent-premarket\" target=\"_blank\">Valeant upsizes debt offering to $3.25B; shares ahead 3% premarket</a> (March 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252388\" data-linked=\"Valeant&#39;s offer to repurchase $1.1B of 6.75% senior debt oversubscribed; shares up 1% premarket\" data-tweet=\"$BHC - Valeant&#39;s offer to repurchase $1.1B of 6.75% senior debt oversubscribed; shares up 1% premarket https://seekingalpha.com/news/3252388-valeants-offer-to-repurchase-1_1b-of-6_75-senior-debt-oversubscribed-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3252388-valeants-offer-to-repurchase-1_1b-of-6_75-senior-debt-oversubscribed-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>102&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}